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Abstract  
The discovery of novel active compounds with new mechanisms of action, higher efficacy and 
improved selectivity is a matter of urgency to multi drug resistance and toxicity problems 
associated with many therapeutic drugs. In the current work S-methyl dithiocarbazate Schiff 
base: SalSmdt, Mp(Smdt)2, VanSmdt, PySmdt and their Zn(II) complexes: 
Zn[(SalSmdt)(H2O)]0.5H2O, Zn2[(Mp(Smdt)2)(CH3COO)], Zn[(VanSmdt)(H2O)] and 
Zn[(PySmdt)(CH3COO)]1.5H2O were synthesized. The Schiff bases were obtained by 
condensation of S-methyl dithiocarbazate (smdt) with different aromatic aldehydes: 
salicylaldehyde (sal), o-vanillin (van), pyridoxal (py) and 2,6-diformyl-4-methylphenol (Mp). 
Additionally, Zn[(phen)2(NO3)2]2H2O, Zn[(aminophen)2(NO3)2]1.5H2O and 
Zn[(Mephen)2(NO3)2]3.5H2O complexes were developed by reaction of Zn(II) with 1,10-
phenanthroline (phen), 4,7-dimethyl-1,10-phenanthroline (Mephen) and 5-amino-1,10-
phenanthroline (aminophen).  All compounds were characterized by elemental analysis, FTIR, 
UV-Vis, NMR, MS and fluorescence spectroscopies. The characterization suggests that the 
Schiff base ligands coordinate the metal ion through the phenolate–O, the imine-N and the sulfur 
atom in the thiol form (except in Zn[(PySmdt)(CH3COO)] for which the thione is proposed). The 
stability of the compounds in buffered aqueous media (5 % DMSO and 95 % PBS, pH 7.4) was 
evaluated and all compounds are stable at least for three hours. The antioxidant potential was 
tested using the 2,2-diphenyl-1-picrylhydrazyl assay. All S-methyl dithiocarbazate Schiff bases 
showed moderate antioxidant activity but the Zn(II) complexes, with the exception of 
Zn[(PySmdt)(CH3COO)], are inactive. The Zn-phenanthroline complexes were tested for their 
DNA binding ability by fluorescence spectroscopy. The results indicate that there is interaction 
between the complexes and calf thymus DNA. Cytotoxicity studies with several tumor cell lines 
(PC-3, MCF-7 and CACO-2) are ongoing. The results obtained for the Schiff bases are 
promising since the IC50 values ranged from 4.41 to 28.99 μM. The phenanthroline ligands and 
their corresponding Zn complexes showed very high cytotoxicity towards A2780 ovarian cancer 
cells, with the Zn complexes showing slightly higher activity than the ligands.  
Keywords: Schiff bases, phenanthroline, Zn(II) complexes,  S-methyl dithiocarbazate, 
cytotoxicity  
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Resumo 
A descoberta de novos fármacos, com mecanismos de acção alternativos, maior eficácia e 
selectividade é urgente para combater os problemas associados à resistência e à toxicidade dos 
fármacos correntes. Neste trabalho bases de Schiff derivadas do S-metil-ditiocarbazato: SalSmdt, 
Mp(Smdt)2, VanSmdt, PySmdt e os seus complexos de zinco(II) foram sintetizados. As bases de 
Schiff foram obtidas através da condensação do S-metil-ditiocarbazato (smdt) com diferentes 
aldeídos aromáticos: salicilaldeído (Sal), o-vanilina (Van) pyridoxal (Py) e 2,6-diformil-4-
metilfenol (Mp) em álcoois. Foram também sintetizados  os complexos  
Zn[(phen)2(NO3)2]2H2O, Zn[(aminophen)2(NO3)2]1.5H2O e Zn[(Mephen)2(NO3)2]3.5H2O 
por reacção do Zn(II) com 1,10-fenantrolina (phen), 4,7-dimetil-1,10-fenantrolina (Mephen) e 5-
amino-1,10-fenantolina (aminophen), respectivamente. Todos os compostos foram 
caracterizados por análise elementar, espectroscopia de FTIR, UV-Vis, RMN, fluorescência e 
espectrometria de massa.  A caracterização sugere que as bases de Schiff coordenam o ião 
metálico através do O-fenolato, o N-imina e o átomo de enxofre na forma tiol (excepto no 
Zn[(PySmdt)(CH3COO)] para o qual se propõe o ligando na forma tiona). A estabilidade dos 
compostos foi avaliada em meio aquoso tamponizado (5 % dmso e 95 % PBS, pH=7.4) tendo-se 
concluído que todos os compostos são estáveis durante pelo menos 3h. O potencial antioxidante 
dos compostos foi testado usando um ensaio com 2,2-difenil-1-picrilhidrazil. Todas as bases de 
Schiff possuem actividade antioxidante moderada, mas os complexos de Zn(II) (excepto o 
Zn[(PySmdt)(CH3COO)]) são inactivos. Os complexos derivados das fenantrolinas foram 
testados quanto à sua capacidade para interagir com o ADN usando espectrofotometria de 
fluorescência e revelaram capacidade, sendo o Zn(aminophen) o mais activo. Encontram-se a 
decorrer estudos de citotoxidade com várias linhas celulares tumorais (PC-3, MCF-7 e CACO-2). 
Os resultados das bases de Schiff são promissores, uma vez que os IC50 são da ordem dos μM 
(entre 4.41 e 28.99). As fenantrolinas e seus correspondentes complexos de Zn(II) mostraram 
citotoxicidade muito elevada nas células tumorais A2780, com os complexos a revelarem 
actividade ligeiramente superior aos ligandos. 
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1. Introduction   
The discovery of novel active compounds with new mechanisms of action, higher efficacy and 
improved selectivity is a matter of urgency to multi drug resistance and toxicity problems 
associated with many therapeutic drugs [1]. Great attention has been given to transition metal   
complexes and extensive biological effects have been found for many of them [2]. One of the 
first therapeutic metallodrugs was salvarsan (-a), an arsenic-based antimicrobial agent developed 
by Paul Ehrlich for the treatment of syphilis. With the addition of mercury and bismuth, 
salvarsan remained the standard remedy for syphilis until it was replaced by penicillin after 
World War II. Salvarsan is regarded as the birth of modern chemotherapy and often cited as the 
beginning of modern research and development of metallodrugs. In 1965, the star of the field, the 
anticancer agent cisplatin, was discovered by Barnett Rosenberg and Loretta VanCamp at 
Michigan State University [3]. This platinum-based (-b) anticancer drug has played a crucial 
role. Complexes with other metal ions like titanium and ruthenium are also being explored with 
some success but none is used in the clinic yet [2,4].  
Despite the achievements in the metal based drugs, especially in platinum-based drugs, they  are 
still associated with many drawbacks such as general toxicity, nonspecific targeting and acquired 
drug resistance, which has stimulated researchers to seek and develop more effective, less toxic, 
and target-specific metal-based drugs [5]. Complexes based on essential transition metals, such 
as Co(II), Ni(II), Cu(II) and Zn(II)  have been found interesting  recently.  These metal ions are 
biocompatible, endogenous and they are present in biological systems [4,5]. They are nowadays 
present in several inorganic drugs used against a variety of diseases [4]. 
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Figure 1 Salvarsan (a) and cisplatin (b) metallodrugs [3] 
Transition metal complexes possess several advantages that make them attractive alternatives to 
organic small molecules for the development of therapeutic agents. They can adopt numerous 
geometries, including square-planar, square-pyramidal, trigonal-bipyramidal and octahedral, 
depending on the coordination number of the metal ion. Many of these geometries are 
unavailable to purely organic molecules, which are limited to linear, trigonal planar or 
tetrahedral shapes because carbon cannot exceed a coordination number of four. The diversity of 
molecular structures afforded by transition metal complexes may therefore allow them to sample 
regions of the chemical space that are inaccessible to organic molecules. Moreover, these metal 
complexes can undergo redox reactions and ligand-exchange reactions inside the body, allowing 
for unique mechanisms of action to take place [6]. In  general, because of the  intrinsic nature of 
their centers, characteristic coordination modes, accessible redox states and kinetic properties 
allow metal complexes to offer potential advantages over organic agents alone [2]. 
The role of the ligands in the metal complex is also very important. For example, they control the 
reactivity of the metal and determine the nature of interactions involved in the recognition of 
biological target sites such as deoxyribonucleic acid (DNA), enzymes and protein receptors. 
Therefore, the choice of ligands for the formation of essential metal -based drugs is crucial. As a 
result, a great expansion of research in the coordination chemistry of sulphur and nitrogen-
containing ligands such as Schiff base and phenanthroline derivatives has taken place during 
recent years [7,8]. 
1,10-phenanthroline (phen) is a classic nitrogen heterocycle and chelating bidentate ligand for 
metal ions. It is a rigid planar, hydrophobic, electron-poor heteroaromatic system, whose 
a) 
 
b)  
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nitrogen atoms are placed in a good position to act cooperatively in cation binding [4]. Its rigid 
structure is imposed by the central ring. That means the two nitrogen atoms are always held in 
fixed positions. They do not have free rotation like the bipyridyl system (Figure 2) [9]. These 
structural features determine its coordination ability towards metal ions [4,9].  
 
Figure 2   Structure of 1,10-Phenanthroline (a) and 2, 2'-dipyridine (b) [9] 
Because of having excellent planar ᴨ systems, phenanthroline and its derivatives have often been 
involved in model compounds to mimic non-covalent interactions in biological processes 
[10,11].  1,10–phenanthroline and its derivatives form very stable complexes with many first-
row transition metals giving compounds with potential therapeutic applications. Figure 3 shows 
examples of metal complexes with mixed-ligands containing 1,10-phenanthroline or its 
derivatives, which have different biological activities [12].  
 
Anticancer [12] 
 
  
Where M = Mn (II), Co (II), Ni (II), Cu (II),  
Zn (II), Cd (II) and Hg (II) 
Antibacterial  [13]         
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Where X= OH, Cl; M = Cu (II), Zn (II), Mn (II), Co (II), and Ni (II) 
Antibacterial [14,15] 
 
Where M = Co (II), n = 1; Ni (II), n= 2 
Antibacterial [16] 
Figure 3 Examples of metal complexes of mixed-ligands containing 1,10-phenanthroline 
derivatives, and its reported biological effects.  
In general, phenanthroline derivatives and their metal complexes have a wide range of biological 
activities such as antibacterial [17], antifungal, antitumor and antiviral activities [4,18]. They 
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interact with DNA by aromatic ᴨ stacking between base pairs. This interaction results in the 
lengthening, stiffening, and unwinding of the helix [18]. 
Schiff bases are organic compounds formed by the condensation reaction of primary amines with 
aldehydes or ketones (Figure 4) under specific condition [19,20,21,22] and were first reported 
by Hugo Schiff in 1864 [20,23]. The common structural feature of Schiff bases (also known as 
imines or azomethines) is a nitrogen analogue of an aldehyde or ketone in which the carbonyl 
group (CO) has been replaced by an imine or azomethine group [20,21,24] and the general 
structural formula is shown  in Figure 4.  
 
Figure 4 General scheme for the formation of Schiff bases [4] 
Schiff bases are used as pigments and dyes, catalysts, intermediates in organic synthesis, and as 
polymer stabilizers [21]. They have also been shown to exhibit a broad range of biological 
activities, including antidiabetic [25], antibacterial, antifungal, anticancer, antioxidant, anti-
inflammatory, antimalarial, antiviral [24], analgesic, antimicrobial, anticonvulsant, antitubercular  
[26], antiproliferative,  antipyretic [21], and diuretic activities [19]. 
Besides the N-donor atom of the azomethine group, Schiff base ligands can possess other donor 
atoms such as O and S in its backbone [27]. The  dithiocarbazate Schiff bases (NH2NHCS2R) 
have received considerable attention because they can provide an interesting series of Schiff 
bases whose properties can be significantly modified by introducing different organic 
substituents (R1, R2, R3 in Figure 5) that impart a variety of donor properties [28]. Because of 
the presence of both hard nitrogen and soft sulfur donor atoms in the backbones of these ligands, 
they readily coordinate with a wide range of transition metal ions yielding stable metal 
complexes, some of which have been shown to exhibit interesting physical and chemical 
properties  and potentially useful biological activities [29]. The biological activities of the metal 
complexes of these Schiff bases differ from those of either the ligand or the metal ion itself [30].  
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For example, Schiff bases derived from S-methyl or S-benzyl dithiocarbazates (Table 1) [27] 
show widely different biological activities, although they may vary only slightly in their 
molecular structure [30].  They can be coordinated to transition metal ions in various modes to 
form stable metal complexes [4,20].  
 
Figure 5 General structure of dithiocarbazate Schiff base derivatives [31]  
Table 1 : List of some dithiocarbazate Schiff base derivatives and their metal complexes  
Ligands (L) Metal complexes  Ref.  
 
Antifungal 
 
Cu(L)2-Antibacterial  and 
anticancer 
Zn(L)2-Anticancer  
 
[32] 
Antibacterial and antifungal 
[Sn(L)2Ph2]  and [Sn(L)Ph2Cl]  
Antibacterial and antifungal 
 
 
 
[33] 
 
 
Antibacterial and antitumor activity 
[Cu2(L)2(CH3COO)](ClO4) 
and  
[Zn2(L)2(ClO4)2]  
Antibacterial and antitumor 
activity 
[30] 
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Antibacterial and antitumor activity 
[Zn(L)2] 
Antibacterial and antitumor 
activity 
 
 
[30] 
 
 
 1= OCH3 at ortho position 
2= OCH3 at meta position 
[M(L1)2]  and [M(L2)2]  where 
M = Cu2+, Ni2+, and Zn2+ 
Cu(L1)2 and Cu(L2)2  showed 
anticancer activity  
[25] 
 
Zinc is an essential trace element in all living systems including animals and humans [1,34]. It is 
the second most prominent trace metal in the human body. Zinc is important for numerous cell 
processes and is a major regulatory ion in the metabolism of cells [35]. It is involved in a wide 
range of cellular processes, including cell proliferation, reproduction, immune function and 
defense against free radicals [36]. It is also required by all cells for activation of a large number 
of Zn-dependent enzymes, which have roles in normal metabolic processes involved in 
biochemical-mediated functions. In addition, Zn-dependent enzymes have many specific key 
roles in overcoming tissue injury or inflammatory disease states [37]. Therefore, developing zinc 
complexes as drugs is very important because it is endogenous and has minimal side effects. 
Many zinc complexes show different biological activities such as treatment of Alzheimer disease 
[38], antibacterial [39], anticonvulsant [40], antiproliferative–antitumor activity [41], antidiabetic 
[34] and anti-inflammatory; all  reported in the literature [35].  
 
Zinc can form complexes with different types of ligands. The properties of zinc complexes also 
depend on the nature of the ligands coordinated to it. The electron donor and electron acceptor 
properties of the ligand, structural functional groups and the position of the ligand in the 
coordination sphere determine the properties of the corresponding zinc complexes [42]. As it was 
 
C
N
H
N
H
S
S
H3CO
  
discussed before, phenanthroline and Schiff base derivatives either in the form of mixed
or alone, have been used to form a lot of metal complexes. There are many zinc complexes with 
different phenanthroline and Schiff base derivatives synthesized and reported in the literature
[7,25,30,43,44,45]. The phenanthroline and Schiff base derivatives coordinate to the zinc ion by 
the nitrogen of the azomethine groups
have shown different biological activities. For example, 
derivatives (see Figure 6) showed 
mixed-ligands norfloxacin and 1,10
phenanthroline have shown very high antibacterial activities
 
Figure 6 Zinc complex with phenanthroline imidazole derivatives (
phen) (b) and [Zn(Naproxen)2 -2,9
 
In addition, zinc complexes with phenanthroline derivatives such as 
dione [7], diphenyl-1,10-phenanthroline, dimethyl
biological activities have also been reported
. These zinc complexes of phenanthroline and Schiff bases 
Zn(II) complexes with phen imidazole 
antibacterial activity [17]. Similarly, the zinc complexes with 
-phenanthroline [46]; naproxen and 2,9
 [47].  
a), Zn(norfloxacin)
-dimethyl-1,10-phen] (c). 
1,10-phenanthroline
-1,10-phenanthroline having
 [48].  
8 
-ligands 
 
-dimethyl-1,10- 
 
 (1,10-
-5,6-
 different 
 9 
 
 
            
 
 
 
 
 
 
         
 
 
 
[7] 
 
 
 
 
                  [11] 
 
[43] 
 
[48] 
Figure 7 Zinc complexes with phenanthroline derivatives and mixed –ligand complexes 
 
As described before in Table 1 , zinc-Schiff base complexes also have been shown to exhibit 
interesting physical and chemical properties and potentially useful biological activities [29].  
 
 
N
N
O
O
N
N
O
O
N
N
O
O
Zn (PF6)2
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The physical and chemical properties of compounds determine their biological activities. For 
example, the rate of absorption, distribution, metabolism and excretion (ADME) of drugs are 
critical parameters in determining their pharmacokinetics properties. This means that the level of 
efficacy and toxicity of the drug depends on its concentration at the site of action [49,50]. This in 
turn depends on the solubility and stability of the drug in aqueous media. Therefore, the drug has 
to be soluble in appropriate solvents and it is very important that it does not precipitate in the 
aqueous environment (or at physiological conditions) and that it is stable (not degradable) in the 
timescale of the studies with biological molecules [51,52,53]. 
Upon entering the cell the drug needs to reach the target or interact / interfere with the relevant 
cellular processes. Radical and reactive oxygen species (ROS) are related with many diseases 
such as inflammation, hypertension, coronary heart disease, atherosclerosis, Alzheimer's disease, 
Parkinson's disease etc. [54]. These free radicals are produced under certain environmental 
conditions and during normal cellular functions in the body. So, antioxidants play an important 
role to protect the human body against damage by radicals [55]. Consequently, evaluation of 
antioxidant activity of new compounds is required.  
Many biological targets including, membranes, proteins, DNA etc. have been used for evaluation 
of biological activities of compounds [56]. The anticancer activity of cisplatin is believed to 
result from its interaction with DNA. The drug reacts with nucleophilic sites in DNA forming 
monoadducts, as well as intra and interstrand crosslinks. This has been used as rationale to 
choose DNA as biological target to evaluate the anticancer activity of other metal complexes 
[57].   
DNA regulates many biochemical processes that occur in the cellular system. The different loci 
present in the DNA are involved in various regulatory processes such as gene expression, gene 
transcription, mutagenesis, carcinogenesis, etc. Transition metal complexes can bind to DNA by 
both covalent and non-covalent interactions. Covalent binding involves the coordination of the 
nitrogenous base or the phosphate moiety of the DNA to the central metal ion. The non-covalent 
binding modes are intercalation, which involves the stacking of the molecule between the base 
pairs of DNA, groove binding, which comprises the insertion of the molecule into the major or 
minor grooves of DNA and electrostatic or external surface binding [5,58].  
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Among these, intercalation is one of the most important DNA binding modes.  The DNA binding 
mode and strength of the affinity are affected by a number of factors, such as planarity of 
ligands, the coordination geometry, the ligand donor atom type, the metal ion type and its 
flexible valence [5,58,59]. 
The main objective of the current work is to develop anticancer drugs. Herein, we report the 
synthesis, characterization and solution behavior of zinc complexes with two classes of ligands: 
S-methyl dithiocarbazate Schiff bases and phenanthroline derived ligands. Stability in aqueous 
media and evaluation of antioxidant activity of the synthesised compounds are reported. The 
DNA binding ability of the zinc phenathroline complexes is also reported.  The cytotoxicity of 
the S-methyl dithiocarbazate Schiff bases as well as that of the phenanthrolines and its Zn-
complexes was evaluated against cancer cell lines and is reported. 
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2. Experimental Part 
2.1. Chemicals and reagents  
1,10-phenanthroline, 2,6-diformyl-4-methylphenol, pyridoxal hydrochloride, hydrazine hydrate 
(all from Sigma-Aldrich), 4,7-dimethyl-1,10-phenanthroline, 5-amino-1,10-phenanthroline (both 
from Alfa Aesar), salicylaldehyde (Acros Organics), methyl iodide, ortho-vanillin  and  carbon 
disulfide were used as received. The zinc metal salts Zn(NO3)24H2O (Fluka Chemika) and 
Zn(CH3COO)22H2O (Panreac) were used as supplied. KOH (Panreac), NaOH (Akzonobel), 
KH2PO4 and Na2HPO4 were used as received.  Solvents such as toluene (CHEM-LAB), ethanol, 
methanol (both from Carlo Erba), isopropanol (Sigma-Aldrich), DMSO (Fisher Scientific), 
diethyl ether (Riedel-de-Häen), acetone-d6, CD3OD, D2O, DMSO-d6 (all from Euriso-top), 
petroleum ether and acetonitrile were used. Phosphate buffered saline (PBS) was purchased from 
Sigma-Aldrich as tablets readily soluble in water (deionized water) giving 0.01 M in phosphate 
(NaCl, 0.138 M; KCl, 0.0027 M), pH 7.4 at 25 ºC. 2,2-diphenyl-1-picrylhydrazyl(DPPH), 
disodium salt of (4-nitrophenyl)-phosphate hexahydrate (PNPP), calf thymus DNA (ctDNA) 
were purchased from Sigma-Aldrich. Millipore® water was used in the experiments with 
biological molecules. All other materials not mentioned here were either analytical or reagent 
grade.  
2.2. Instrumentation  
Elemental analysis for C, H, N and S were carried on a FISONS EA 1108 CHNS-O apparatus at 
Laboratório de Análises of Instituto Superior Técnico. The NMR spectra were recorded at 
ambient temperature on a Bruker Avance II + 300 (Ultra Shield TM Magnet) spectrometer 
operating at 300.13 MHz. The 1H NMR chemical shifts are reported in ppm using 
tetramethylsilane as internal reference. The Infra-Red spectra were recorded on Alpha RT-
DLaTGS HR 0.8 FTIR spectrometer and the UV-Visible absorption spectra were recorded on a 
Perkin Elmer Lambda 35 UV-Vis spectrophotometer with 10.0 mm optical path cuvettes. A 500-
MS Varian Ion Trap Mass Spectrometer was used to measure ESI-MS spectra of methanolic 
solutions of the ligands and complexes in both positive and negative modes. Ultimate 3000 
HPLC system (Dionex) equipped with C18 (12.5×0.4 cm, 5 µm particles) and connected to 
chromeleon software was used. Fluorescence measurements were carried out on a SPEX® 
  
Fluorolog spectrofluorimeter (Horiba JobinYvon) in a FL3
Xenon lamp and in a 10.0 mm quartz cuvette. The instrumental response was corrected by means 
of a correction function provided by the manufacturer. The experiments were carri
temperature and are all steady-state measurements.
2.3. Phenanthroline
2.3.1. Synthesis 
The zinc complexes with phenanthroline derivatives were synthesized following procedures 
reported in the literature for similar compounds
         Where  
         R1 = R2 = H: Zn[(phen)2(NO
         R1 = NH2, R2 = H: Zn[(aminophen)
Scheme 1 Synthesis of the 
 
Zn[(phen)2(NO3)2]2H2O : An ethanolic solution (1
(180 mg, 1 mmol) was added drop
tetra hydrate (Zn(NO3)24H2O) (130.7
immediately. The mixture was stirred 
white solid was then collected by filtration, washed with 
and ethyl ether. Finally, the product
64.0 %). ESI-MS (electro spray ionization mass spectra) (MeOH) 
- 11 configuration, equipp
 
 derived zinc complexes  
 
 [10,60,61]. 
3)2]2H2O; R1 = H, R2 = CH3: Zn[(Mephen)2(NO
2(NO3)2]1.5H2O 
zinc(II) complexes with phenanthroline derived
 ml) of 1,10-phenanthroline monohydrate 
 wise to a stirred ethanolic solution (1.5 ml) of zinc nitrate
 mg, 0.5 mmol). A white precipitate was formed 
for 2 h at room temperature and left overnight at
a small amount of cold
 was dried over silica gel under vacuum. 
m/z [Calculated (Found)]: 
13 
ed with a 
ed out at room 
 
3)2]3.5H2O;  
 ligands 
 
 4 ºC. The 
 water, acetone 
(Yield: 176 mg, 
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486.04 (486.04) (90 %) [M(phen)2(NO3)]
+; 212.3 (212.0) (14 %) [M(phen)2]
2+. Elemental 
analysis for C24H16N6O6Zn2H2O: C, 48.90 %; H, 3.49 %; N, 14.26 %. Found: C, 48.9 %; H, 3.1 
%; N, 14.1%. FTIR (KBr, cm-1):  1620 (C=N), 1579 (C=C), 579 (Zn-N). 1H NMR (300 MHz, 
DMSO-d6, δ (ppm)): 8.1-9.0 (aromatic-Hs). 13C NMR (300 MHz, DMSO-d6, δ (ppm)): 126.3-
149.3 (aromatic-Cs). UV-Vis [DMSO, λmax / nm (ε / M
-1cm-1)]: 325 (1.17×103), 294 (1.28×104), 
272 (3.59×104), 267 (3.76× 104).  
Zn[(Mephen)2(NO3)2]3.5H2O: An ethanolic solution (2 ml) of 4,7-dimethyl-1,10-
phenanthroline (208 mg, 1 mmol) was added drop wise to a stirred ethanolic solution (1.5 ml) of 
zinc nitrate tetra hydrate (Zn(NO3)24H2O) (130.7 mg, 0.5 mmol). A light brown precipitate was 
formed immediately. The mixture was stirred for 2 h at room temperature and left overnight at 4 
ºC. The solid was then collected by filtration, washed with a little amount of cold water, ethanol 
and ethyl ether. After drying over silica gel under vacuum, a beige solid product was obtained. 
(Yield: 239 mg, 78.9 %). ESI-MS (electro spray ionization mass spectra) (MeOH) m/z 
[Calculated (Found)]: 542.12 (542.0) (14 %) [M(Mephen)2(NO3)]
+; 240.1 (240.3) (100 %) 
[M(Mephen)2]
2+.  Elemental analysis for C28H24N6O6Zn3.5H2O: C, 50.60 %; H, 4.60 %; N, 
12.60 %. Found: C, 50.6 %; H, 4.7 %; N, 12.5 %.  FTIR (KBr, cm-1): 1615 (C=N), 1576 (C=C), 
639 (Zn-N). 1H NMR (300 MHz, Methanol-d4, δ (ppm)): 2.9-3.0 (aliphatic-Hs), 7.7-9.0 
(aromatic -Hs). 13C NMR (300 MHz,Methanol-d4, δ (ppm)): 19.3 (aliphatic-C), 124.8-152.5 
(aromatic-Cs).  UV-Vis [DMSO, λmax / nm (ε / M
-1 cm-1)]: 327 (1.59×103), 305 (7.18×103), 274 
(3.60×104), 268 (3.5×104). 
Zn[(aminophen)2(NO3)2]1.5H2O: Methanolic solution (4 ml) of  5-amine-1,10-phenanthroline 
(201.9 mg, 1 mmol) was added drop wise to a stirred ethanolic solution (1.5 ml) of zinc nitrate 
tetra hydrate (Zn(NO3)24H2O) (130.7 mg, 0.5 mmol). The yellow clear mixture was stirred at 
room temperature for 2 h and then refluxed at 70 ºC for more 3 h, after which an orange 
precipitate was formed. After cooling to room temperature the mixture was kept at 4 ºC 
overnight. The solid was then filtered under vacuum, washed with a little amount of cold water, 
acetone and ethyl ether. After drying over silica gel under vacuum, a yellow solid product was 
obtained. (Yield: 236 mg, 81.40 %). ESI-MS (electro spray ionization mass spectra) (MeOH) m/z 
[Calculated (Found)]: 516.10 (516.10) (10%) [M(aminophen)2(NO3)]
+; 227.00 (227.3) (100 %) 
[M(aminophen)2]
2+.  Elemental analysis for C24H18N8O6Zn1.5H2O: C, 47.50 %; H, 3.50 %; N, 
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18.50 %. Found: C, 47.5 %; H, 3.1 %; N, 18.4 %.  FTIR (KBr, cm-1):  1615 (C=N), 1593 (C=C), 
513 (Zn-N). 1H NMR (300 MHz, Methanol-d4, δ (ppm)): 7.15-9.1 (aromatic -Hs). 
13C NMR (300 
MHz, Methanol-d4, δ (ppm)): 103.35-149.38 (aromatic-Cs). UV-Vis [DMSO, λmax / nm (ε / M
-1 
cm-1)]: 363 (1.86×104), 298 (5.19×104),  268 (4.42×104). 
From this point further the hydration water molecules included in the complex formulation will 
be omitted for simplicity, unless relevant. Also, sometimes the complexes will be referred to as 
Zn(phen)2, Zn(Mephen)2 and Zn(aminophen)2. 
2.3.2. Stability studies in aqueous medium  
The stability of the Zn(II) complexes of phenanthroline derived ligands was evaluated using UV-
Vis, fluorescence and NMR spectroscopies. 
In the UV-Vis absorption study, 500 μM of Zn[(Mephen)2(NO3)2] and 1000 µM of 
Zn[(phen)2(NO3)2] or Zn[(aminophen)2(NO3)2] stock solutions of the complexes were prepared 
in DMSO. Then, further dilutions were done containing 125 μl of the stock solution and 2375 μl 
of PBS buffer (pH 7.4,10 mM), having the final  concentrations 25 µM for Zn[(Mephen)2(NO3)2] 
and 50 μM for Zn[(phen)2(NO3)2] and Zn[(aminophen)2(NO3)2]. UV-Visible absorption spectra 
(260-500 nm) were recorded and monitored for 24 h. Similarly, for the fluorescence studies stock 
solutions of the complexes with concentrations of 500 μM were prepared in DMSO. By 
dissolving 125 μl of the stock solutions in 2375 μl PBS, diluted solutions with a concentration of 
25 µM were prepared. Then, the fluorescence emission spectra of Zn[(phen)2(NO3)2] (332-700 
nm), Zn[(Mephen)2(NO3)2] (350-700 nm) and Zn[(aminophen)2(NO3)2] (455-700 nm) were 
recorded at 326, 345 and 450 nm excitation wavelengths, respectively. To evaluate the stability, 
the emission spectra were recorded at 3 h and 72 h.   
The stability study by NMR was carried out for Zn[(phen)2(NO3)2] only. The reason is that this 
complex was found to be less stable when compared to Zn[(Mephen)2(NO3)2] and 
Zn[(aminophen)2(NO3)2], when evaluated by UV-Visible spectrophotometry. 
A phosphate buffer solution with concentration 120 mM and pH of 7.54 was prepared by 
dissolving 2.4 mg KH2PO4 and 14.4 mg Na2HPO4 salts in 1 ml of D2O.  12.5 mg of 
Zn[(phen)2(NO3)2] were dissolved in 250 µl of DMSO-d6. Then, 20 µl of this solution were 
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mixed with 380 µl of the phosphate buffer giving 5 % DMSO and 95 % PBS. Finally, the 
stability of the compound was studied for 24 h by 1H-NMR spectroscopy.  
2.3.3. DNA binding ability study  
Binding ability to DNA can be evaluated directly by titration of the complex (at constant 
concentration) with ctDNA and following spectroscopic absorption [62] or fluorescence 
emission spectra changes [48,63]. Alternatively, when the complex does not show fluorescence 
emission, the binding ability can be determined indirectly by a competition titration using a 
probe [ethidium bromide (EB) or thiazole orange (TO)] bound to ctDNA (at constant 
concentration)  and following the quenching of the emission of fluorescence due to displacement 
of  probe bound to ctDNA by the target compound [64,65]. 
The ﬂuorescence quenching and enhancement can be evaluated by classical Stern–Volmer 
Equation 1 [65] and   Equation 2 [48] respectively.  
Io/I = 1 + KQ[Q] 
Equation 1 
Io/I = 1 – KE[E]    
  Equation 2 
Where  Io and I are the ﬂuorescence intensity in the absence and presence of quencher / enhancer 
respectively.  [Q] and [E] are the concentration of quencher and enhancer respectively. KQ and 
KE are the Stern–Volmer quenching and enhancement constants, respectively. 
The binding assay was carried out based on reported procedures [59,66].  The stock solution of 
ctDNA was prepared by dissolving 1 mg into 1 ml PBS buffer (pH 7.4, 10 mM). The stock 
solution was kept at 4 oC for 2 days to allow dissolution of the DNA and used within 4 days. The 
DNA concentration of the stock solution was determined using the molar absorption coefficient 
6600 M−1cm−1 at 260 nm. The UV absorbance ratio at 260 and 280 nm of ctDNA solution was 
determined and the values were found to be 1.84, which indicate that the ctDNA is sufficiently 
free from protein.  0.5 mM stock solutions of the metal complexes were prepared in DMSO. 
Several samples with different DNA:Zn complex molar ratios (ca. 0; 0.2; 0.4; 0.6; 0.8; 1.0; 2.0; 
4.0) were prepared maintaining the concentration of the metal complex solutions at 25 µM (in 5 
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% DMSO and 95 % PBS) and gradually increasing the concentration of ctDNA. The Absorbance 
values at the emission and excitation wavelengths were kept below 0.2. The ﬂuorescence 
emission spectra were measured with the following parameters: λex= 326, 345 and 450 nm (for 
Zn(phen)2, Zn(Mephen)2 and  Zn(aminophen)2 respectively) and both slits were of  5 nm. All the 
experiments were carried out at 25 oC. 
2.3.4. Evaluation of antioxidant activity  
The DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging method has been widely used to 
evaluate the free radical scavenging activity of various antioxidant substances. It is a rapid 
technique for screening the radical scavenging activity of specific compounds and has been used 
by many researchers [55,67]. This assay is based on the measurement of the decrease in 
absorbance of DPPH at 516 nm after reaction with the test compound. The effect of antioxidants 
on DPPH radical scavenging is due to the hydrogen donating ability or radical scavenging 
activity of the samples [55]. 
The scavenging reaction between (DPPH) and an antioxidant (H-D) can be written as: 
 
Antioxidants react with DPPH, a stable free radical that is thus reduced, and as a result the 
absorbance decreases due to the formation of the DPPH-H from the DPPH radical. The degree of 
discoloration also indicates the scavenging potential of the antioxidant compounds or samples in 
terms of hydrogen donating ability [55]. 
Stock solutions of complexes Zn[(phen)2(NO3)2] (0.86 mM), Zn[(Mephen)2(NO3)2] (0.86 mM), 
and Zn[(aminophen)2(NO3)2] (1.21 mM) were prepared in DMSO. By dissolving 2.4 mg of 
DPPH (2,2-diphenyl-1-picrylhydrazyl) in 50 ml of methanol, a DPPH stock solution with 
concentration 121.7 µM was prepared and kept in the dark during the entire experiment. Then, 5 
samples having different n(compound) / n(DPPH)  mole ratios and a final volume of 2500 µl 
were prepared by mixing 1500 µl of DPPH, and different volumes of the compounds’ solutions 
and methanol. The samples were vigorously shaken and kept in the dark for 30 minutes. Finally, 
the spectra were recorded between 300 and 700 nm, so that the absorbance values at 516 nm 
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could be read. The antioxidant activity (% scavenging activity) was calculated using Equation 3 
[55] below.  
         
Equation 3 
Where Abs0 = the absorbance of the control DPPH solution, and Abs1 = the absorbance in the 
presence of sample solutions or standards for positive control. The value for IC50 was determined 
by a linear regression where the % of scavenging activity is 50 and compared with that of  
ascorbic acid, a  standard which was used as positive control [68].  
2.4. S-methyl dithiocarbazate derived Schiff bases and their zinc 
complexes  
2.4.1. Synthesis  
The S-methyl dithiocarbazate derived Schiff bases and their corresponding zinc(II) complexes 
were prepared following previously reported methods [32] with some modifications. 
S-methyl dithiocarbazate (Smdt): Potassium hydroxide (1.14 g; 20 mmol) was dissolved in 9:1 
ethanol-water mixture (7 ml) and cooled in ice. To the mixture, excess hydrazine hydrate (1 g; 
0.98 ml; 30 mmol) was added slowly with stirring. The reason to add an excess of hydrazine 
hydrate was to compensate the loss due to its volatile nature. Carbon disulphide (1.52 g; 1.207 
ml; 20 mmol) in ethanol (1.25 ml) was then added drop wise from a burette, with constant 
vigorous stirring over a period of 1 h. The temperature of the mixture was kept below 10 oC 
during the addition. A yellow oil was formed, separated with a funnel and dissolved in 2:3 
ethanol-water mixture (5 ml) and the solution was cooled in ice. Methyl iodide (2.9 g; 1.272 ml; 
20 mmol) was added slowly, with vigorous stirring. Ice-cold water (5 ml) was then added and the 
stirring was continued for another 10 minutes. The white solid product was separated by 
filtration, washed with water; and dried in air. The crude product was recrystallized from toluene 
(9 ml). Yield:  8.142 g (33.3 %); mp: 80 ºC. Elemental analysis for C2H6N2S2: C, 19.66 %; H, 
4.95 %; N, 22.92 %; S, 52.47 %. Found: C, 19.5 %; H, 4.8 %; N, 23.0 %; S, 53.8 %. 
  
Scheme 
 
Salicylaldehyde S-methyl dithiocarbazate Schiff base
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 was added. Additionally, 30 ml of methanol
 h and the solution became colorless.  After coo
 with 10 ml of cold MeOH and 30
 vaccum. (Yield: 0.206 g, 72.82
m/z [Calculated (Found)]: 227.03
-H]-. Elemental analysis for C9H10N2OS2: C, 47.77
 %; H, 4.3 %; N, 12.3 %; S, 28.8 %.  
 (C=N), 967 (C=S).  1H NMR (300 MHz, Acetone
C2 -H), 6.99 (t, 1H, C4 -H), 7.38 (t, 1H, C3-H), 
1H, O-H), 12.25 (s, 1H, N-H). 13C NMR (300 MHz,
2), 118.17 (C6), 120.57 (C4), 132.38 (C5), 133.
10). UV-Vis [DMSO, λmax / nm (ε / M
-1 cm-1)]: 
103). RP-HPLC (50 % ACN: 50 % Water, R
3 Synthesis of SalSmdt ligand 
19 
 
 dithiocarbazate 
Then, 
 was added. The 
ling, the white 
 ml 
 %). ESI-MS 
 (227.0) (18 %) 
 %; H, 4.45 
FT-IR (KBr, cm-
-d6, δ (ppm)): 
7.48 (d, 1H, C5-
 Acetone-d6, 
20 (C3), 149.36 
367 (2.68×104), 
T / min): 
 
  
Methyl-phenol-di-S-methyl dithiocarbazate Schiff base
S-methyl dithiocarbazate was dissolved in  5
methylphenol was also prepared
two solutions were mixed and allowed to
formed. After cooling, the solid was 
and dried under vacuum. (Yield:
(MeOH) m/z [Calculated (Found)]: 373.02 (372.9
743.03 (742.7) (100 %) [2L-H]-
H, 4.33 %; N, 15.04 %; S, 34.42
(KBr, cm-1): 3433 (OH), 3103 (NH), 
δ (ppm)): 2.30 (s, 3H, C7-H), 2.57
16-H), 10.81 (s, 1H, O-H), 13.51
(C14 & 18), 19.79 (C7), 119.64 (C
(C1), 197.45 (C11 & 20). UV-Vis [
(2.61×104), 344 (3.83×104), 330 (3.64
Scheme 
 
o-Vanillin S-methyl dithiocarbazate Schiff base (Van
(0.1515 g, 1.25 mmol) was dissolved in 
added under stirring.  The reaction mixture was refluxed for 3 h and the white solid product was 
formed. After cooling, the product was filtered, washed with 10
ml of petroleum ether. Finally, it was allowed to dry
 Mp(Smdt)2: 0.2446 
 ml of methanol.  A solution of 2,6
 by dissolving 0.1640 g (1.0 mmol) in 15 ml of
 reflux for 4 h under stirring. A yellow 
filtered, washed with methanol followed by petroleu
 0.32 g, 85.9 %). ESI-MS (electrospray ionization mass spectra) 
) (12 %) [L+H]+; 371.01 (371.3) (83
. Elemental analysis for C13H16N4OS4: Calculated: 
 %. Found: C, 42.0 % ; H, 4.4 %; N, 14.7 %; S,
 1617 (C=N), 1039 (C=S). 1H NMR (300 MHz,
 (s, 6H, C14 & 18-H), 7.57 (s, 2H, C3 & 5 -H), 8.52
 (s, 2H, N-H). 13C NMR (300 MHz, DMSO-d6
2 & 6), 129.61 (C4), 131.30 (C3 & 5), 144.75 (C
DMSO, λmax / nm (ε / M
-1 cm-1)]: 394 
×104). RP-HPLC(50 % ACN:50 % Water, R
4 Synthesis of Mp(Smdt)2 ligand 
Smdt): S-methyl dithiocarbazate 
20 ml isopropanol. o-Vanillin (0.198 g, 1.25
 ml of cold isopropanol and 30
 under vacuum. (Yield: 0.1846
20 
g (2.0 mmol)  of 
-diformyl-4-
 methanol. The 
precipitate was 
m ether 
 %) [L-H]-, 
C, 41.91 %; 
 34.2 %. FT-IR 
 DMSO-d6, 
 (s, 2H, C8 & 
, δ(ppm)): 16.80 
8 & 16), 154.55 
(2.41×104), 383 
T / min): 8.8.  
 
 mmol) was 
 
 g, 57.6 %). 
  
ESI-MS (electro spray ionization mass spectra) (MeOH) 
(257.04) (25 %) [L+H]+; 255.02
Calculated:  C, 46.86 %; H, 4.72
10.9 %; S, 25.6 %.  FT-IR (KBr, cm
NMR (300 MHz, Acetone-d6, δ (ppm)): 2.
H), 7.06 (d, 1H, C3-H), 7.18 (d, 1H,
N-H). 13C NMR (300 MHz, Acetone
(C6), 120.32 (C4), 121.98 (C5), 
[DMSO, λmax / nm (ε / M
-1 cm
(6.79×103). RP-HPLC (50 % AC
Scheme 
 
Pyridoxal S-methyl dithiocarbazate Schiff base (Py
g, 2.5 mmol) was dissolved in 40
pyridoxal hydrochloride (0.5091 
15 min at room temperature. The reaction 
product was formed. The mixture was 
petroleum ether. Finally, the product was dried under vacuum. 
MS (electro spray ionization mass spectra) (MeOH) 
(100 %) [L+H]+; 270.03 (270.18)
analysis for C10H13N3O2S2: C, 44.26
H, 4.8 %; N,15.4 %; S, 24.3 %
m/z [Calculated (Found)]: 257.04 
 (255.14) (100 %) (L-H)-. Elemenal analysis for C
 %; N, 10.93 %; S, 25.01 % . Found: C, 46.7 
-1): 3416 (O-H), 3178 (N-H), 1616 (C=N), 
63 (s, 3H, C13-H), 3.87 (s, 3H, C15 -H), 
 C5-H), 8.56 (s, 1H, C7-H), 9.65 (s, 1H, O-H), 13.34
-d6, δ (ppm)): 17.18 (C13), 56.49 (C15), 114.86
146.74 (C2), 148.74 (C7), 149.19 (C1), 199.10
-1)]: 367 (1.92×104 ), 363 (2.04×104), 339 (2.53
N:50 % Water, RT / min): 4.5. 
5 Synthesis of VanSmdt ligand 
Smdt): S-methyl dithiocarbazate (0.3055
 ml methanol and NaOH (0.100 g; 2.5 mmol) was added
g, 2.5 mmol) was slowly added and the mixture was stirred for 
mixture was refluxed for 3 h and the white solid 
cooled, filtered, and washed with 50 ml water and 50
(Yield: 0.5674 g, 86
m/z [Calculated (Found)]: 272.05 (272.04)
 (100 %) [L-H]-; 541.07 (540.73) (49 %) [2L
 %; H, 4.83 %; N, 15.49 %; S, 23.63 %. Found: C, 44.0
. FT-IR (KBr, cm-1): 2930-3357 (br, OH & NH), 
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10H12N2O2S2: 
%; H, 4.7 %; N, 
1073 (C=S). 1H 
6.90 (t, 1H, C4-
 (s, 1H, 
 (C3), 119.06 
 (C10). UV-Vis 
×104), 292 
 
 
. Then, 
 ml 
.64 %). ESI-
 
-H]-. Elemental 
 %; 
1612 (C=N), 
  
1047 (C=S). 1H NMR (300 MHz,
4.63 (s, 2H, C16 -H), 5.34 (s, 1H, 1
14-OH), 13.74 (s, 1H, NH). 13C 
59.21 (C16), 120.20 (C5), 133.31 
(C10). UV-Vis [DMSO, λmax/nm (
103). RP-HPLC (50 % ACN:50 %Water, R
Scheme 
 
Zn[(SalSmdt)(H2O)]0.5H2O: 194
was added to an ethanolic solution (25
stirring for 15 min at room temperature. Then, the mixture was 
Finally, the solid was filtered, washed with
g, 83.6 %). ESI-MS (electro spray ionization mass spectra) (MeOH) 
353.00 (352.5) (100 %) [ML+2CH
analysis for ZnC9H10N2O2S20.5
%.  Found: C, 34.0 %; H, 3.0 %
H2O)), 1593 (C=N), 952 (C-S). 
6.8 (t, 1H, C6-H), 7.00 (d, 1H, C2
13C NMR (300 MHz, Acetone-d
133.50 (C1), 135.38 (C5), 161.29
400 (1.197×104), 319 (8.412×10
min): 6.3. 
 DMSO-d6, δ (ppm)): 2.42 (s, 3H, C15-H), 2.6
7–OH), 8.04 (s, 1H, C7-H), 8.81 (s, 1H, C4-H
NMR (300 MHz, DMSO-d6, δ (ppm)): 17.12 (C
(C6), 138.73 (C7), 145.79 (C4), 147.13 (C2), 150.03
ε / M-1 cm-1)]: 351 (1.83×104), 339 (2.05×10
T / min): 2.78. 
6 Synthesis of PySmdt ligand 
 mg (8.84×10-4 mol) of zinc acetate (Zn(CH
 ml) of SalSmdt (0.100 g; 4.42×10-4 mol) with constant 
refluxed for 2 
 30 ml of water and dried in vacuum.
m/z [Calculated (Found)]: 
3OH-H2O+H]
+, 610.89 (611.1) (100 %) [2ML
H2O: Calculated: C, 33.75 %; H, 3.59 %; N, 8.75
; N,8.4 %; S, 19.6. FTIR (KBr, cm-1): 3315-3667
1H NMR (300 MHz, Acetone-d6, δ (ppm)): 2.44
 -H), 7.25 (t, 1H, C1 -H), 7.39 (d, 1H, C5-H), 8.73
6, δ (ppm)): 14.46 (C9), 118.25 (C6), 120.56 (C
 (C7), 165.10 (C3). UV-Vis [DMSO, λmax / nm (ε
3), 291 (8.767×103). RP-HPLC (50 % ACN:50
22 
1 (s, 3H, C13-H), 
), 10.61 (s, 1H, 
13), 19.18 (C15), 
 (C1), 197.52 
4), 298 (6.849× 
 
3COO)22H2O) 
h under stirring.  
 (Yield: 0.1184 
-H]-. Elemental 
 %; S, 20.02 
 (br, OH (from 
 (s, 3H, C9-H), 
 (s, 1H, C7-H). 
2), 122.65 (C4), 
 / M-1 cm-1)]: 
 % Water, RT / 
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Zn2[(Mp(Smdt)2)(CH3COO)]: 
to an ethanolic solution (25 ml) of 
for the first hour at room temperature. Then, the reaction was kept under stirring for extra 2
reflux temperature and a yellow product was formed. The 
filtered and washed with ethanol
ESI-MS (electro spray ionization mass spectra) (MeOH) 
587.87(588.0) (60 %) [ML+CH3
32.21 %; H, 2.88 % ;N, 10.02 % 
. FT-IR (KBr, cm-1):  1613 (C=N
MHz, DMSO-d6, δ (ppm)): 1.05
7.41 (s, 2H, C1 & 5 -H), 8.69 (s, 
13.95 (C12 & 17), 19.36 (C7), 138.88
1cm-1)]: 432 (1.176×104), 349 (1.5
RT / min): 6.1. 
Zn[(SalSmdt)(H2O)]0.5H2O complex 
117.8 mg (5.367×10-4 mol) of Zn(CH3COO)22H
MP(Smdt)2  (100 mg; 2.68×10
-4 mol)  with constant stirring 
mixture was cooled, 
 (30 ml) and dried under vacuum. (Yield: 0.0619
m/z [Calculated (Found)]: 
OH]-. Elemental analysis for C15H16N4O3S4Zn
; S, 22.93 %.  Found: C, 32.2 % ; H, 3.3 %; N, 
), 1460 (COO)asy, 1375 (COO)sym, 1000 (C-S
 (s, 3H, C28-H), 2.24 (s, 3H, C7-H), 2.43 (s, 6
2H, C8  & 9 -H). 
13C NMR (300 MHz, DMSO
 (C1 & 5), 159.64 (C8 & 9). UV-Vis [DMSO, 
58×104), 310 (1.547×104). RP-HPLC (50 % ACN:50
23 
 
2O) was added 
 h at 
the product 
 g; 41.29 %). 
2: Calculated: C, 
9.9 %; S, 21.7 % 
). 1H NMR (300 
H, C12 & 17-H), 
-d6, δ (ppm)): 
λmax / nm (ε / M
-
 % Water, 
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Zn[(VanSmdt)(H2O)]: 68.5 mg 
to  an ethanolic solution (25 ml) of 
the first  30 min, at room temperature. Then the reaction was refluxed at 80
stirring.  A light yellow solid product was formed and 
with 30 ml ethanol and dried under vacuum.
ionization mass spectra) (MeOH) 
(2ML+H2O-H)
-. Elemental analysis
8.29 %; S, 18.99 %.  Found: C,
3427(OH from H2O), 1597 (C=N
3H, C11-H), 3.72 (s, 3H, C7-H), 6.39 (m
13C NMR (300 MHz, DMSO-d6
152.09 (C2) and 159.84 (C9). UV
(8.90× 103), 292 (6.86×103). RP-
 
Zn2[(Mp(Smdt)2)(CH3COO)] complex 
(3.12×10-4 mol) zinc acetate (Zn (CH3COO)22H
VanSmdt (0.080 g; 3.12×10-4 mol) with constant stirring for 
 o
cooled. The product was 
 (Yield:  0.0493 g, 46.79 %). ESI-MS (electro spray 
m/z [Calculated (Found)]: 670.91(670.85)
 for C10H12N2O3S2Zn: Calculated: C, 35.56 %; H,
 35.2 %; H, 2.5 %; N,7.7 %; S, 19.4 %. FTIR (KBr, cm
), 1034 (C-S). 1H NMR (300 MHz, DMSO-d6, 
, 1H, C6 -H), 6.82 (m, 2H, C1&5 -H),  8.55
, δ (ppm)): 14.17 (C11), 55.65 (C7), 113.17 (C
-Vis [DMSO, λmax / nm (ε / M
-1 cm-1)]: 406 (7.69
HPLC (50 % ACN:50 % Water, RT / min): 4.67
24 
 
2O) was added 
C for 2 h under 
filtered, washed 
 (100 %) 
 3.58 %; N, 
-1): 
δ (ppm)): 2.41(s, 
 (s, 1H, C9 -H).  
6), 126.43 (C5), 
×103), 328 
. 
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Zn[(PySmdt)(CH3COO)]1.5H
of methanol and stirred for 20 min
(Zn(CH3COO)22H2O) was also
mixture was refluxed for 2 h at refluxing temperature
the solution became orange but there was no formation of precipitate. The 
concentrated under reduced pressure
and allowed to cool. Finally, the product was filtered, washed by diethyl 
under vacuum. (Yield:  250 m
(MeOH) m/z [Calculated (Found)]:
%) (ML+H2O+H)
+; 392.00 
C12H15N3O4S2Zn1.5H2O: Calculated: 
C, 34.9 %; H, 4.0 %;  N, 9.4 %; S, 
(C=N), 1493 (COO)asy, 1304 (COO)
2.39 (s, 3H, C12-H), 2.44 (s, 3H, 
-H), 8.92 (s, 1H, C9-H), 11.97 (s,
(C13), 21.35 (C12), 59.51 (C7), 131.40
and 178.43 (C20). UV-Vis [DMSO, 
298 (6.849×103). RP-HPLC (50 % ACN:50
Zn[(VanSmdt)(H2O)] complex 
2O: 271 mg (1.00×10
-3 mol) of PySmdt was dissolved in 20
 at room temperature. 220 mg (1.00×10-3 mol
 added and stirred at room temperature for extra 20
 under constant stirring. After 2
. Then, the product was precipitated by adding 
ether (30
g, 59.75 %). ESI-MS (electro spray ionization mass spectra) 
 333.97 (334.1) (100 %) (ML-CH3COO)
+; 412.00 
(392.21) (13 %) (ML-H)-. Elemental
C, 34.45 %; H, 4.24 %; N, 10.04 %; S, 15.33 %
14.6 %. FT-IR (KBr, cm-1): 3417 (OH from H
sym, 1022 (C-S).  
1H NMR (300 MHz, DMSO
C13-H), 4.51 (s, 2H, C7 -H), 5.18 (s, 1H, 8-OH),  
 1H, NH).  13C NMR (300 MHz, DMSO-d6, 
 (C6), 133.45 (C4), 153.78 (C2), 155.82 (C
λmax / nm (ε / M
-1 cm-1)]: 420 (7.160×103), 338 (
 % Water, RT / min): 4.71. 
25 
 
 ml 
) zinc acetate 
 min. The 
 h reflux, 
solution was 
diethyl ether 
 ml) and dried 
(411.6) (80 
 analysis for 
.  Found: 
2O), 1597 
-d6, δ (ppm)): 
7.43 (s, 1H, C6 
δ (ppm)): 14.13 
9), 161.71 (C3) 
8.094× 103), 
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2.4.2. Stability studies in aqueous m
The stability of the ligands and their corresponding Zn
Visible spectroscopy, following the procedure 
Stock solutions of both ligands and 
2000 μM for Smdt, VanSmdt
Zn[(SalSmdt)(H2O)], Zn2[(Mp(Smdt)
the  ligands Mp(smdt)2, SalSmdt
125 μl of the stock solution and 2375 μl
concentrations of 100 µM for Smdt
complexes Zn[(SalSmdt)(H2O)] 
SalSmdt and PySmdt in 5 % DMSO and 95
PBS, 125 µl of the complex stock 
concentration.  UV-Visible absorption 
h for ligands and 48 h for complexes. 
The stability of these compounds was also evaluated by RP
carried out using the following procedure
eluent were filtered and degassed
ligands and zinc complexes with concentrations of 1
50 % water solvent mixture. Then, the solutions were filtered using 
Zn[(PySmdt)(CH3COO)]1.5H2O  complex
edium  
(II) complexes was evaluated 
described below.  
complexes were prepared in DMSO with a concentration of 
 and Zn[(PySmdt)(CH3COO)]; 500 µM for
2)(CH3COO)] and Zn[(VanSmdt)(H2O)]; and 250
 and PySmdt. Then, further dilutions were  prepared
 of  PBS buffer (pH 7.4, 10 mM), having the  
, VanSmdt and Zn[(PySmdt)(CH3COO)]
and Zn[(VanSmdt)(H2O)]; 12.5 µM for the  ligands 
 % PBS. For Zn2[(Mp(Smdt)2)(CH3COO)]
solution was diluted in 2375 µl DMSO  to prepare 25
spectra (260-500 nm) were recorded and monitored for
 
-HPLC. The RP-HPLC analysis was 
. The acetonitrile and MilliQ water used 
 by sonication.  Individual sample solutions of Schiff
 mM were prepared in 50 % acetonitrile and 
0.2 µm PTFE
26 
 
 
by UV-
 complexes 
 µM for 
 containing 
final  
; 25 µM for 
Mp(smdt)2, 
 instead of 
 µM final 
 24 
to prepare the 
 base 
. Finally, the 
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sample solutions were eluted on a C18-column (12.5×0.4 cm, 5 µm particles) with an isocratic 
eluent composed of acetonitrile and water (50 % CH3CN:50 % H2O) over 20 min. The injection 
volume and flow rate was 20 µl and 1 ml / min, respectively. The chromatograms were recorded 
at 260, 330, 350 and 375 nm and the stability of the compounds was evaluated based on the 
analysis of the chromatogram. 
2.4.3. Evaluation of antioxidant activity 
The evaluation of the antioxidant activity was done with DPPH as reported in section 2.1.4.  
2.4.4. Phosphatase activity  
Phosphatase activity is one of the important functions among the wide range of enzymatic roles 
of divalent zinc ions that has been used as basis for extensive studies of various functional 
mimics of phosphoesterases.  Over the years Zn(II) complexes have been  studied as phosphate 
ester models taking into account their extraordinary Lewis acidity, redox rigidity, nucleophile 
generation, leaving group stabilization and physiological relevance [69]. Therefore, the aim of 
this experiment is to evaluate if the synthesized Zn(II) complexes are capable of promoting the 
hydrolysis of phosphate monoesters. 
The phosphatase activity of the zinc complexes was carried out using the disodium salt of (4-
nitrophenyl) phosphate hexahydrate (PNPP) as monophosphate ester substrate based on reported 
procedures [70]. 500 µM stock solutions of the complexes were prepared in DMSO. The stock 
solution of PNPP (20 mg / 1 tab) with concentration 2.69 mM was prepared by dissolving 1 
tablet in 20 ml PBS.  Then, three samples: diluted complex solution without PNPP, diluted PNPP 
solution without complex and the mixture of complex and PNPP at fixed C(compound) / 
C(PNPP)  concentration  ratio  in a final volume of 3 ml were prepared. PBS was used for the 
dilution. Finally, the UV-Visible absorption spectra were recorded between 260 and 600 nm at 
25 oC and 37 oC for all samples. The absorption spectra were recorded at least for 1 h with 20 
min interval and the absorbance changes between 400-430 nm were evaluated.  
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2.5.  Cytotoxicity study  
The cytotoxicity effect of the synthesized compounds against cancer cells was carried out either 
at Universidade da Beira Interior by Samuel Silvestre (the dithiocarbazate compounds) or at 
Centre for Nuclear Sciences and Technologies by Fernanda Marques (the phenanthroline 
compounds). For the Schiff bases, the procedure was the following: The tumor cell lines PC-3 
(prostate), MCF-7 (breast) and CACO-2 (intestinal) were cultured at 37 °C in a humidified air 
incubator with 5 % CO2. PC-3 cells were cultured in RPMI 1640 medium with 10 % fetal bovine 
serum and 1 % of the antibiotic mixture of 10,000 U/ml penicillin G and 100 mg / ml of 
streptomycin. The high-glucose Dulbecco´s modified Eagle medium (DMEM) supplemented 
with 10 % fetal bovine serum and 1 % antibiotic / antimycotic (10,000 U/ml penicillin G, 100 
mg / ml streptomycin and 25 µg /ml anfothericin B) was used to culture MCF-7 cells. CACO-2 
cells were also cultured in DMEM medium supplemented with 10 % FBS and 1 % of the 
antibiotic mixture of 10,000 U/ml penicillin G and 100 mg /ml of streptomycin.  
The in vitro antiproliferative effects were evaluated by the MTT ([3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide]) assay. Cells were tripsinized and counted by the trypan-blue 
exclusion assay and then 100 µl of cell suspension / well with an initial density of 2×104 cells/ml 
was seeded in 96-well culture plates  and left to adhere for 48 h. After the cells adherence, the 
medium was replaced by several solutions of the compounds in study (30 µM for screening assay 
and 0.01, 0.1, 1, 10, 50 and 100 µM for concentration-response studies) in the appropriate 
medium for approximately 48 h. The percentage of DMSO in cell culture medium did not exceed 
1%. 5-fluorouracil (5-FU) was used as positive control and untreated cells were used as the 
negative control. Each experiment was performed in quadruplicate and independently repeated at 
least two times.  After the incubation period, the medium was removed and 100 µl of phosphate 
buffer saline (NaCl 137 mM; KCl 2.7 mM, Na2HPO4 10 mM and KH2PO4 1.8 mM in deionized 
water and pH adjusted to 7.4) were used to wash the cells. Then 100 µl of the MTT solution (5 
mg/ml) was prepared in the appropriate serum-free medium and was added to each well, 
followed by incubation for 4 h at 37 °C. Then after, the MTT containing medium was removed 
and the formazan crystals were dissolved in DMSO. Then the absorbance was measured at 570 
nm using a microplate reader. Cell viability values were expressed as percentages relative to the 
absorbance determined in the cells used as negative controls.  
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Cytotoxicity effects of the Zn(II)(Rphen) complexes on A2780 (ovarian) cancer cell line were 
also evaluated by MTT assay using 96-well plates. The cell line was cultured at 37 °C in a 
humidified air incubator with 5 % CO2. The compounds were first dissolved in DMSO and then 
in medium through serial dilutions ranging from 0.01 μM to 100 μM. The final DMSO 
concentration did not exceed 1% (v/v) in either control or treated cells and under these 
conditions it had no effect on the cellular activity. After treatment with the complexes for 
different time periods, the cell medium was replaced by 200 µl (0.5 mg/ml) of a MTT solution in 
PBS and further incubated for 3 h at 37°C. The resulting purple formazan from tetrazolium 
reduction were solubilized in DMSO and gently dissolved. Finally, the absorbance of control and 
treated cells was measured at 575 nm using a microplate reader.  The cytotoxicity of the 
complexes was expressed as the IC50 calculated from dose-response curves using the GraphPad 
Prism software.  
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3. Results and discussion 
Two families of zinc complexes were synthesized. Reaction of zinc nitrate tetra hydrate, 
Zn(NO3)24H2O, with commercially available phenanthroline derived ligands at room 
temperature in methanol yielded Zn(Rphen)2 type complexes (R= H, NH2 or CH3). Additionally, 
the Schiff base ligands were synthesized by the condensation reaction of aromatic aldehydes and 
S-methyl dithiocarbazate in methanol / isopropanol at refluxing temperature for 3-4 h. Similarly, 
zinc complexes were prepared from the reaction of zinc acetate dihydrate, Zn(CH3COO)22H2O, 
with the Schiff base ligands in methanol / ethanol at  room temperature for the first 20-60 min 
and then at refluxing temperature for 1-2 h.  The solid products were filtered, washed and dried 
under vacuum. All the synthesized compounds are soluble in DMSO except 
Zn[(VanSmdt)(H2O)], which is only sparingly soluble. The reaction’s percentage yields ranged 
from 64.0 to 81.4 for the zinc complexes with phenanthroline derivatives; 33.3 to 86.6 for the 
Schiff base ligands; and 41.3 to 83.6 for the zinc complexes with the Smdt Schiff base ligands. 
The elemental analysis and spectroscopic characterization results are discussed in the following 
sections. 
3.1. Zinc complexes with phenanthroline derivatives 
3.1.1. Characterization   
Results of elemental analysis data are given in Table 2. The percentage of carbon, hydrogen and 
nitrogen in all the zinc complexes were in good agreement with the calculated values for the 
proposed structures. All complexes contain water molecules. 
Table 2: Analytical data for the zinc complexes with phenanthroline derivatives 
Compound  Elemental analysis calculated (found) (%) 
   C      H     N 
Zn[(phen)2(NO3)2]2H2O 48.90 (48.9) 3.49 (3.1) 14.26 (14.1) 
Zn[(aminophen)2(NO3)2]1.5H2O 47.50 (47.5) 3.50 (3.1) 18.50 (18.4) 
Zn[(Mephen)2(NO3)2]3.5H2O 50.60 (50.6) 4.60 (4.7) 12.60 (12.5) 
The UV-Vis absorption spectra measured for the phenanthroline derivative ligands and their 
corresponding zinc complexes in DMSO at room temperature are depicted in Figure 8. Zn(II) 
  
has  d10 closed-shell electronic configuration.  Therefore, d
spectra of zinc complexes [71]. 
.
Figure 8  UV-Visible absorption spectra for phenanthroline derivative ligands and their zinc
complexes in DMSO at room temperature
The absorption bands at 274, 
respectively, may be attributed to
[48,72,73].  These bands were observed 
and 274 nm in the absorption spectra of Zn
Zn[(Mephen)2(NO3)2] complexes
have formed complexes with the
–d transitions are not expected in the 
 
 
282 and 268 nm of phen, aminophen and Mephen ligands,
 π→π* transitions of the azomethine chromophore
at higher wavelengths (bathochromic shift)
[(phen)2(NO3)2], Zn[(aminophen)
, respectively. These bathochromic shifts imply that
 zinc ion through their azomethine group [
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(II) 
 
 (C=N) group 
: 294, 298 
2(NO3)2] and 
 the ligands 
37]. In addition, 
  
spectral bands observed at 268, 264, and 268
group of phen, aminophen and Mephen ligands
at 267, 268 and 268 nm 
Zn[(Mephen)2(NO3)2] complexes
indicating that there is no participation of this group in the coordination. 
and 326 nm for phen, aminophen and Mephen, respectively,
transitions in the phenanthroline
wavelength shifts except for Zn
shift for the azomethine group 
confirm that there is formation of complexes
Fluorescence emission spectra of the zinc complexes
in DMSO with excitation wavelengths
and Zn(Mephen)2, respectively, 
show emission maxima at 489 and 470
The emission spectrum for Zn(phen)
be attributed to the intraligand emission (
complexes’ fluorescence intensity enhancement
to coordination to Zn(II), reducing the non
due to increased rigidity in the coordinated ligands
Figure 9 Fluorescence emission 
room temperature in DMSO.  
 nm may be assigned to π→π* transition
, respectively. These spectral bands are observed 
for Zn[(phen)2(NO3)2, Zn[(aminophen)
, respectively, which shows that there are no significant shifts 
Weak bands
 may also be attributed
. In the case of their corresponding zinc complexes, there is no 
[(aminophen)2(NO3)2] to 363 nm. In general, the bathochromic 
and higher extinction coefficients (higher absorption intensity) 
 [74,75]. 
 with phenanthroline derivatives were taken 
 of 326, 450 and 345 nm for  Zn(phen)2, 
at room temperature. The spectra are depicted in 
 nm for Zn(aminophen)2 and Zn(Mephen)
2 is very weak and is not presented. The emission 
ᴨ→ ᴨ*) from their corresponding ligands. 
, when compared to the free ligands
-radiative decay of the intraligand excited state
. 
 
spectra of complexes of zinc with phenanthroline
32 
s of ‘C=C’ 
2(NO3)2] and 
 at 324, 345 
 to n→π* 
Zn(aminophen)2 
Figure 9 and 
2, respectively. 
bands may 
The 
 may be due 
 [72], 
 derivatives at 
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The complexes were also characterized by ESI-MS in the positive and negative modes and for all 
complexes it was possible to assign molecular peaks. The spectra showed peaks at m/z 212.02 , 
227.29 and 240.33 that are due to the [Zn(phen)2]
2+, [Zn(aminophen)2]
2+ and [Zn(Mephen)2]
2+ 
species, respectively.  The assignments for these and other peaks corresponding to different 
species are presented in Table 3. 
Table 3: Assignment of ESI-MS peaks of the Zn(Rphen)2(NO3)2 complexes. L stands for the 
phenanthroline derivative. 
Compound  Peak assignment m/z (mass %) 
Theoretical  Found 
Zn[(phen)2(NO3)2] ML2(NO3)
+ 486.04 486.06 (90%) 
ML2
2+ 212.26 212.02 (14%) 
Zn[(aminophen)2(NO3)2] ML2(NO3)
+ 516.10 515.96 (10%) 
ML2
2+ 227.00 227.29 (100%) 
Zn[(Mephen)2(NO3)2] ML2(NO3)
+ 542.12 541.96 (14%) 
ML2
2+ 240.10 240.33 (100%) 
 
The IR spectra of the free phenanthroline ligands were also compared with that of their 
corresponding zinc complexes to determine the changes that have taken place during 
complexation. The infrared bands of the characteristic groups of the ligands and their complexes, 
together with their assignments are listed in Table 4. The assignments were done based on the 
information obtained from previous works reported in the literature for similar compounds 
[13,14,15,17]. 
The IR spectra of the phen, Mephen and aminophen ligands show characteristic bands at 1636, 
1628 and 1667 cm-1, respectively, due to the stretching of the (C=N) functional group. Bands at 
1622, 1611 and 1568 cm-1 were also found, due to C=C stretching vibrations. In the IR spectra of 
the corresponding complexes, there were shifts in wave numbers for both groups.  The IR 
spectral band values of (C-H) of the aromatic rings are observed at around 838-856 cm-1 and 
729-743 cm-1 in the free ligands. These were red shifted to 821-858 cm-1 and 725-727 cm-1, 
respectively, in their corresponding complexes. All these shifts can be explained by the fact that 
each nitrogen atom of the heterocycle donates a pair of electrons to the central zinc metal 
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forming a dative bond [14,15]. The IR spectra of all the complexes show new bands of Zn-N 
appearing at 579, 513, and 639 cm-1 for Zn[(phen)2(NO3)2],  Zn[(aminophen)2(NO3)2] and 
Zn[(Mephen)2(NO3)2], respectively which are not observed in the corresponding free  ligands 
[13,14]. 
Table 4: IR spectral assignments (cm−1) of phenanthroline derivative ligands and their 
corresponding zinc complexes 
Compound  C=C C=N C-H Zn-N 
Zn[(phen)2(NO3)2]2H2O  1579  1620 850 579 
   725  
Phen 1622 1636 856 ---- 
   743  
Zn[(aminophen)2(NO3)2]1.5H2O  1593  1615 821 513 
   727  
Aminophen 1611 1667 838 ---- 
   735  
Zn[(Mephen)2(NO3)2]3.5H2O  1576  1615 858 639 
   727  
Mephen 1568 1628 852 ---- 
   729  
 
NMR spectroscopy is very important to identify the groups through which the ligands form their 
corresponding metal complexes and confirm the proposed structures. 1D (1H and 13C) and 2D 
(DEPT, COSY, HSQC and HMBC) NMR experiments were done for all ligands and zinc 
complexes. The 1H NMR and 13C NMR spectra of phen and Zn(phen)2, recorded at room 
temperature in DMSO-d6 and the chemical shifts are given in Table 5 and Table 6 respectively. 
In the 1H NMR spectra of phen, it was possible to observe four types of aromatic protons 
appearing in the range of 7.7-9.1 ppm. In its corresponding Zn(phen)2 complex, these protons are 
shifted  downfield, appearing in the range of 8.1 - 9.0 ppm. In the 13C NMR spectra, the chemical 
shift of the aromatic carbons of phen appear in the range of 123.5 - 150.1 ppm, but in its zinc 
complex the carbon peaks appear in the range 126.3-149.3 ppm, of which the majority show a 
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downfield shift. The downfield shift in both 1H and 13C NMR peaks of the zinc complexes 
confirms the complex formation of phen with Zn(II) ion through the aromatic ring nitrogen 
atoms, since coordination removes electron density from the ligand, and consequently, a 
deshielding effect [37].  
 
Scheme 11 Zn(phen)2 complex 
Table 5: 1H NMR chemical shifts (δ / ppm) for phen ligand and Zn(phen)2 complex  in DMSO-
d6 solvent. 
Compound  δ /  (multiplicity, number of protons) 
 H1 & H11   H5 & H13 H7  & H8   H6  & H12 
Zn(phen)2 8.97 (d,4H) 8.75 (s,4H, br) 8.36 (s,4H) 8.08 (s,4H, br) 
phen 9.10 (d,1H) 8.46 (d,1H) 7.94 (s,1H) 7.74 (m,1H) 
s – singlet, d - doublet, t - triplet, m – multiplet, br-broad 
Table 6: 13C chemical shifts (δ / ppm) for phen ligand and Zn(phen)2 complex using 300 MHz in 
DMSO-d6 solvent 
Compound  δ / ppm of 13C 
C1 & C11 C2 & C9 C3 & C10 C5 & C13 C6 & C12 C7 & C8 
Zn(phen)2 140.6 129.2 139.7 149.3 126.3 127.6 
phen 145.8 128.6 136.4            150.1           123.5    126.9 
 
The 1H and 13C NMR characterization was also done for the aminophen ligand and its complex 
Zn(aminophen)2  in CD3OD at room temperature, as it is depicted in Figure 10 and Figure 11. 
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The aromatic protons and carbons of aminophen in the 1H and 13C NMR spectra appear in the 
range of 6.99-9.07 ppm and 104.63-150.41 ppm, respectively. In the Zn(aminophen)2 complex 
these are shifted to 7.15- 9.06 ppm and 103.35-149.38 ppm, respectively.  
a)  
 
b)  
 
Figure 10 1H NMR spectra of Zn(aminophen)2(a) and aminophen (b) in CD3OD at room 
temperature 
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a)  
 
b)  
 
                     Figure 11 13C NMR spectra of Zn(aminophen)2 (a) and aminophen (b) in CD3OD 
at room temperature 
As it can be seen from the 1H and 13C NMR spectra of the complex, there are extra proton and 
carbon peaks, which suggests that more than one species is formed in solution. To help the 
assignment a titration of Zn(aminophen)2 with increasing amounts of aminophen ligand was 
carried out. Therefore, solutions with different molar ratios of Zn:L were prepared to see trends 
in the  intensity of each  peak of the 1H NMR spectra, which in turn enabled to understand the 
behavior of complexation in solution (Figure 12). It is expected that the addition of free ligand 
will favor the formation of 1:3 species:  
  Zn(aminophen)2 + aminophen > Zn(aminophen)3.  
  
Figure 12 1H NMR titration of Zn(aminophen)
Where : a=500µl complex + 0 µl ligand
100µl ligand; d = 0µl complex + 500 µl ligand
 Zn: L = 1:3 Zn(aminophen)3 and 
 
We propose that the following equilibrium takes place in solution, upon dissolution of the 
Zn(aminophen)2(NO3)2: 
Scheme 12 Chemical equilibrium
in CD3OD solution at room temperature
2 with aminophen in CD3OD at room temperature
; b = 500µl complex + 20 µl ligand; c = 500µl complex + 
 and   standing for  Zn:L = 1:2  Zn(aminophen)
 aminophen ligand.  
 of Zn(aminophen)2 (1:2) in solution with another 1:3 species 
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The 1H and 13C NMR spectra of Mephen ligand and Zn(Mephen)2 complex were also measured 
in CD3OD at room temperature (see Figure 13 and Figure 14). The 
1H NMR spectrum of 
Mephen ligand showed aromatic proton peaks in the range 7.53- 8.87 ppm and aliphatic ones at 
2.27 ppm. The 13C NMR spectra of this ligand also showed aromatic carbon peaks in the range 
of 123.28-150.32 ppm and aliphatic carbons at 18.91 ppm.  On the other hand, the 1H NMR 
spectra of Zn(Mephen)2 showed aromatic proton peaks in the range 7.70- 8.97 ppm and aliphatic 
ones in the range 2.92-2.97 ppm. And also, the 13C NMR spectra of this complex showed 
aromatic and aliphatic carbon peaks in the range of 124.83-152.46 and 19.26 ppm, respectively. 
Again, downfield shifts are observed for both the protons and carbons’ chemical shift of the 
Mephen moiety in the 1H and 13C NMR spectra of the Zn(Mephen)2 complex, indicating  the 
formation of a complex of Mephen with Zn (II) ion through the aromatic ring nitrogen atoms. 
a)  
 
b)  
 
                       Figure 13 The 1H NMR spectra of Zn(Mephen)2 (a) and Mephen (b)  in CD3OD 
at room temperature 
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a)  
 
b)  
 
                       Figure 14 The 13C NMR spectra of Zn(Mephen)2 (a)  and MePhen (b) in CD3OD 
at room temperature 
Again, due to formation of more than one species in solution, probably involving ligand 
exchange, additional proton and carbon peaks appeared in the NMR spectra of the complex.  For 
this reason, it was difficult to make the assignment and 1H NMR titration of Zn(NO3)24H2O 
with Mephen  was  performed to get insight into the complexation behavior. 
A75 mM solution of Zn(NO3)24H2O  in 0.7 ml CD3OD was prepared.  20.4 µl of TMS (internal 
reference) and 31.24 mg of Mephen were mixed and dissolved in 2 ml of CD3OD to prepare a 
solution with the same concentration (75 mM) of each compound. Then, the 1H NMR spectra of 
the mixtures of Zn(NO3)2 and Mephen at different Zn to Mephen mole ratios: 0:1 (0:500 µl); 1:1 
(250:250 µl); 1:2 (200:400 µl); 1:3 (120:370 µl) and 1:4 (100:400 µl) were recorded (see Figure 
  
15). The 1H NMR spectroscopic titration
there was formation of species with different 
Figure 15  1H NMR spectra of the reaction mixture of Zn(NO
different  Zn to Mephen mole ratios
 
 
 
 
 of the zinc ion with Mephen proved the
stoichiometries in solution. 
3)24H2O and  Mephen  solution at 
 in CD3OD at room temperature 
41 
 assumption that 
 
  
Figure 16 1H NMR spectra of aromatic (a) and 
Zn(NO3)4H2O and Mephen at different mole ratios
stands for Zn:L=1:1  Zn(Mephen
free Mephen ligand.  
a)  
b)  
aliphatic (b) regions of the reaction 
 in CD3OD at room temperature
), Zn:L = 1:2  Zn(Mephen)2,  Zn:L =1:3 Zn(Mep
42 
 
 
 mixture of 
  where   
hen)3 and  
  
As can be seen from observation of
intensity of the initial aromatic and aliphatic 
formed. The intensity of the newly formed peaks increases as the am
increases. This indicates that the
of Mephen ligand, as is expected
will give another 1:1 and 1:3 species in solution and the 
Scheme 13 Chemical equilibrium of 
in CD3OD  at room temperature. Sol = 
Therefore we can conclude that upon dissolution of the solid complex three species are present in 
solution corresponding to Zn:L molar ratios of 1:1, 1:2 and 1:3.
3.1.2. Stabilit
Analysis of biological systems requires work under aqueous 
complexes’ speciation and their characteristics
necessary to ensure that the complexes do not precipitate in the aqueous environment (at 
physiological pH), and that they are stable
[66,76]. 
The stability of Zn(phen)2, Zn(aminophen)
UV-Vis, fluorescence and NMR spectroscopies 
containing 5 %  of DMSO, which is essential to solubilize 
 the spectra in Figure 16, upon addition of Mep
proton peaks decreases whereas new peaks are 
ount of added ligand 
 trend of species formation is 1:1→1:2 →1:3 up
. Therefore, it can be understood that the Zn (Mephen)
 equilibrium is described
Zn (Mephen)2 with two other species (1:1 and 1:3 species)
solvent molecule 
 
y 
conditions. Thus, knowing t
 in aqueous solution is very important. It is 
 (not hydrolyzed) in the timescale of the studies
2 and Zn(Mephen)2  complexes was
in PBS buffered solutions (at physiological pH)
the metal complexes. Phosphate 
43 
hen ligand the 
on the addition 
2 complex 
 as follows.  
 
 
he 
 
 evaluated with 
 
  
buffer saline (PBS) was chosen due to its compos
solution match those of the human body.  
As it can be seen in Figure 17, the UV
zinc complexes in 5 % DMSO and 95
slight increase in the absorption 
assumed that the zinc complexes 
the necessary reactions required for bioactivity
ition, since the ion concentrations 
 
-Vis absorption intensity and shape of the spectra of the 
 % PBS did not show significant changes for 
intensity for Zn(phen)2 and Zn(Mephen)2.  Therefore, it can be 
are stable enough in the physiological environment to undergo 
.  
a)  
b)  
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of the 
24 h, except a 
 
 
  
Figure 17 UV-Vis absorption spectra of 
25 µM Zn(Mephen)2 (c) with increasing time
h and 24 h) in 5 % DMSO and 95
The stability of the complexes was also 
spectra are depicted in Figure 18
On the other hand, the emission intensity of Zn
decrease through time. However, 
show any changes. Once again the stability of the complexes is corroborated
c)  
 
50 µM Zn(phen)2 (a), 50 µM Zn(aminophen)
 ( t0, 5 min, 10 min, 20 min, 30 min, 1
 %  PBS. 
evaluated by fluorescence spectroscopy and 
. The emission intensity of Zn(phen)2 slightly increased at  3
(aminophen)2  and Zn(Mephen)2
the shape of the emission spectra for all of complexes
.  
a)  
b)  
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2 (b) and 
 h, 2 h; 3 h, 4 
the emission 
 h.  
 showed a slight 
 did not 
 
 
  
Figure 18 Fluorescence emission spectra of 25
Zn(Mephen)2 (c)  with increasing time ( t
The stability study by NMR was 
buffer solution with pH 7.54 was prepared
dissolved in 250 µl of DMSO-d
mixed with 380 µl of the phosphate buffer solution which 
Then, the stability of the compound was studied 
Figure 19 1H NMR spectra of Zn
c)  
 µM Zn(phen)2 (a), Zn(aminophen)
0 ,  3 h,  72 h)  in  5 % DMSO and 95 %  PBS.
also carried out for Zn[(phen)2(NO3)2]2H2O only
 in 1 ml of D2O.  12.5 mg Zn(aminophen)
6. Then, 20 µl of the Zn(aminophen)2 DMSO
contain 5 % DMSO and 95
for 24 h by monitoring the 1H NMR
[(phen)2in  DMSO-d6 : D2O (5%:95 %) over 24 h
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2 (b) and  
 
. A phosphate 
2 was 
-d6 solution was 
 % PBS. 
 spectra.  
 
. 
  
The 1H NMR spectra of Zn(phen)
hydrolysis and no precipitate formation ob
3.1.3. Antioxidant activity
As it is described in the experimental 
related with many diseases [54]
very important, since it may be a 
activities of the Zn(Rphen)2 complexes was evaluated with a widely used free radical scavenging 
method which uses DPPH (2,2-diphenyl
The detailed procedure followed is described in the experimental section.  
of the mixture of the test compound
300 and 700 nm. Then, by following 
free radical scavenging ability of the test
antioxidant activity as it can be seen in
Figure 20 UV-Vis absorption spectra measured for solutions containing DPPH (
MeOH) and different % (n / n) of 
nCompound / nDPPH mole ratio (0.00
 
2 show that the compound is  stable in solution, with no 
served over a period of 24 h. 
 
section, radical and reactive oxygen species (ROS) are
. Thus, evaluating the antioxidant activity of the
key to understanding their biological activity. The antioxidant 
-1-picrylhydrazyl) [55,67]. 
The absorption 
s and DPPH in different mole ratios were scanned 
the intensity trend at 516 nm, it was possible to evaluate the 
ed compounds. None of the compounds showed 
 Figure 20 for Zn(phen)2, as an example. 
Zn(phen)2. (↓) indicates decreasing intensity 
 %, 25.81 %, 49.27 %, 75.07 %, 100.88 %).
47 
 
 compounds is 
spectra 
between 
 
73 μM in 
with increasing 
 
  
3.1.4. DNA binding ability
The DNA binding ability of the compounds was
because it regulates many biochemical processes tha
since the Zn-phenanthroline complexes contain large aromatic systems that can 
DNA through intercalation, their binding ability was evaluated.
fluorescent and, thus a direct fluorescence method was used. That 
complex (at constant concentration) with ct
The fluorescence emission spectra
for Zn(phen)2 and Zn(Mephen)
confirms that there is an interaction between the test compounds and DNA
different mechanisms for the aminophen complex and the other two 
 
 also evaluated. DNA is an important
t occur in the cellular system 
 The studied
means that
DNA was carried out.  
 intensity increased for Zn(aminophen)2 and slightly decrease
2 as the concentration of ctDNA increased (Figure
, which should involve 
[48,63]. 
48 
 drug target 
[5,58]. Thus, 
potentially bind 
 complexes are 
 titration of the 
d 
 21). This 
 
 
  
Figure 21 Fluorescence spectral changes of 
Zn(aminophen)2 (c) on the titration of in
5 % DMSO and 95 % PBS (λex
decreasing and increasing of the fluorescence intensity respectively. 
The ﬂuorescence quenching and enhancing 
classical Stern–Volmer equation 1
obtained for Zn(aminophen)2 is included in
obtained is 8.1×103 M-1. The fluorescence enhancement suggests that upon interaction of the 
complex with DNA the complex becomes more protected from deactivation by the polar water 
molecules. Several mechanisms may be involved but the differences found for the three 
complexes suggest that intercalation in between the base pairs should not be acting. This
surely lead to fluorescence enhancement, which does not happen with two of the studied 
complexes. So we propose a nonintercalative docking of the complexes within the min
groove. Additionally, the amino group might be involved in hydrogen bonds with the phosphate 
groups.  Further studies should be done to better understand the mechanisms involved and the 
differences found for the 3 complexes.
25 µM Zn(phen)2 (a), Zn(Mephen)
creasing amounts of ctDNA (r= [DNA]
 (nm) = 326 (a), 345 (b), 450 (c)):Arrows (↓)  and  (
 
ability of the compounds can be evaluated by 
 [65] and equation 2 [48] respectively. The Stern Volmer plot 
 Figure 22. The Stern-Volmer enhancement constant 
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2 (b) and 
 / [Complex]) in 
↑), refers 
 would 
or/major 
  
Figure 22 Stern –
 
3.2. S-methyl dithiocarbazate
corresponding zinc
3.2.1. Characterization 
The analytical data for the percentage of carbon, hydrogen, nitr
S-methyl dithiocarbazate Schiff base
with that of the calculated values for the proposed structures
Zn(II) ion is tetra coordinated with the ligands coordinated to the metal ion through the phenolate 
oxygen, the imine nitrogen and the sulfur atom from the dithiocarbazate, and either a water 
molecule or an acetate ion occupies the 4
The S-methyl dithiocarbazate Schiff base 
between the thiol and the thione forms (see 
state the ligands are in the thione form and in most complexes (except Zn(PySmdt)) the ligands 
are coordinated with the sulphur in the thiol form (see
 
 Volmer plot for Zn(aminophen)2. λem = 589 nm
 derived Schiff base ligands and their 
 complexes 
 
ogen and sulfur in all the studied
 ligands and their zinc complexes were in a good agreement 
 (Table 7). We propose that the 
th position of the tetrahedron. 
ligands can be involved in tautomeric equilibrium 
Scheme 14). The analysis suggest that in the solid 
 also the FTIR section). 
50 
 
 
 51 
 
 
Scheme 14 The tautomeric equilibrium of the S-methyl thiocarabazate Schiff bases 
 
Table 7: The elemental data of S-methyl dithiocarbazate derived Schiff base ligands and their 
zinc(II) complexes 
Compound  Elemental analysis calculated (found) (%) 
 C H N S 
SalSmdt 47.77 (47.6) 4.45 (4.3) 12.38 (12.3) 28.33 (28.8) 
Mp(Smdt)2 41.91 (42.0) 4.33 (4.4) 15.04 (14.7) 34.42 (34.2) 
VanSmdt 46.53 (46.1) 4.76 (4.5) 10.85 (10.8) 24.84 (25.4) 
PySmdt 44.26 (44.0) 4.83 (4.8) 15.49 (15.4) 23.63 (24.3) 
Zn[(SalSmdt)(H2O)]0.5H2O 33.75 (34.0) 3.59 (3.0) 8.75 (8.4) 20.02 (19.6) 
Zn2[(Mp(Smdt)2)(CH3COO)] 32.21 (32.2) 2.88 (3.3) 10.02 (9.9) 22.93 (21.7) 
Zn[(VanSmdt)(H2O)] 35.56 (35.2) 3.58 (2.5) 8.29 (7.7) 18.99 (19.4) 
Zn[(PySmdt)(CH3COO)]1.5H2O 34.45 (34.9) 4.24 (4.0) 10.04 (9.4) 15.33 (14.6) 
The studied compounds were characterized by UV-Vis absorption spectroscopy and their 
electronic spectra in DMSO at room temperature are depicted in Figure 23. The electronic 
spectrum of Mp(Smdt)2  shows absorption bands at 310 and 330 nm which may be attributed to 
π→π* transitions of the aromatic  ring; 344 nm assigned to π→π* transition of azomethine 
moiety and 383 nm with 394 nm (shoulder) attributed to n→π* of groups containing lone pair of 
electrons. In the spectrum of the Zn2[(Mp(Smdt)2)(CH3COO)] complex, the absorption band of 
  
the azomethine group shifted to 349
disappeared. Whereas, a new band at 
transfer (LMCT) from the phenolate to the Zn ion. Similarly, in all ot
LMCT band is present at ca. 430 nm, and the intraligand bands are less intense and blue shifted. 
This might be due to increased planarity of the ligand upon coordination to the metal ion, which 
might increase the overall conjugat
 nm and the bands due to groups with lone pair of el
432 nm appeared which is due to ligand to metal charge 
her zinc(II) complexes the 
ion of the ligand system.  
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Figure 23 UV-Visible absorption spectra for S
ligands and their zinc(II) complexes in DMSO at room temperature
The compounds were also characterized by ESI
molecular peaks of all ligands were identified in both 
spectra.  Moreover, other peaks of both the ligands and complexes were detected in the spectra 
which all are supporting evidence for the
Table 8: Assignment of ESI-MS 
and their zinc(II) complexes  
 Compound  S
SalSmdt (L+H)
(L
 
-methyl dithiocarbazate derived Schiff
 
-MS and the data is included 
positive and negative mode 
 proposed structures of compounds.   
peaks for S-methyl dithiocarbazate derived Schiff base ligands 
pecies  m/z 
Theoretical F
+ 227.03 22
-H)- 225.01 225.3
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 base 
in Table 8.  The 
ESI-MS 
ound 
7.0 (18%) 
 (100%) 
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Mp(Smdt)2 (L+H)
+ 373.02 372.9 (12%) 
(L-H)- 371.01 371.3 (83%) 
(2L-H)- 743.03 742.7 (100%) 
VanSmdt (L+H)+ 257.04 257.0 (25%) 
(L-H)- 255.02 255.1 (100%) 
PySmdt (L+H)+ 272.05 272.0 (100%) 
(L-H)- 270.03 270.2 (100%) 
(2L-H)- 541.07 540.7 (49%) 
Zn[(SalSmdt)(H2O)] (ML+2CH3OH-
H2O+H)
+ 
353.00  352.5 (100%) 
(2ML-H)- 610.89 611.1 (100%) 
Zn2[(Mp(Smdt)2)(CH3COO)] (ML+CH3OH)
- 587.87 588.0 (60%) 
Zn[(VanSmdt)(H2O)] (2ML + H2O-H)
- 670.91 670.85 (100%) 
Zn[(PySmdt)(CH3COO)] (ML-CH3COO)
+ 333.97 334.1 (100%) 
(ML+H2O+H)
+ 412.00  411.6 (80%) 
(ML-H)- 392.00 392.21 (13%) 
 
The IR analysis result of the S-methyl dithiocarbazate derived Schiff base ligands were also 
compared with that of their corresponding zinc complexes which is used as supporting evidence 
for the formation of the complexes.  The infrared bands of the characteristic groups of the 
ligands and their complexes together with their assignments are listed in Table 9 [77]. The 
assignments were done based on reported values [25,30,32].  The IR spectra of the Schiff base 
ligands show bands of NH and OH in the range of 3357-2435 and 3103-3178 cm-1 respectively.  
The bands for azomethine group (C=N) and C=S appeared in the range of 1612-1617 and 967-
1073 cm-1 respectively. None of the compounds exhibited any band at ca. 2700 due to S-H, so all 
data corroborate that all ligands are in the thione form in the solid state. On the other hand, the 
bands for OH group in the complexes appear in the range of 3315-3427 cm-1, due to coordinated 
water molecules. The NH and C=S bands are absent in the spectra of all the complexes due to the 
coordination of the ligands to the metal ion through the azomethine and thiol groups 
respectively.  
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In the IR spectra of the complexes, bands appearing between 1593-1613 cm-1 are assigned to 
stretching vibration of the C=N moiety, showing shifts when compared to that of the 
corresponding ligands. The new C-S bands appearing at 952-1034 cm-1 can be used as evidence 
for the formation of the complexes, and coordination of the ligand as the thiol tautomer. Other 
new bands appeared at1460 cm-1 and 1375 cm-1 in the Zn2[(Mp(Smdt)2)(CH3COO)] spectra and 
at 1493 cm-1 and 1304 cm-1 in the Zn[(PySmdt)(CH3COO)]1.5H2O spectra, corresponding to 
asymmetric (COO)asy and symmetric (COO)sym, which confirm coordination of the acetate ion 
[77]. 
Table 9:  IR spectral assignments (cm−1) of S-methyl dithiocarbazate derived Schiff base ligands 
and their corresponding zinc(II) complexes 
Compound  Ѵ(cm-1) 
O-H N-H C=N C=S C-S (COO)asy (COO)sym 
SalSmdt 3435 3111 1616 967 - - - 
Mp(Smdt)2 3433 3103 1617 1039 - - - 
VanSmdt 3416 3178 1616 1073 - - - 
PySmdt 2930-3357 1612 1047 - - - 
Zn[(SalSmdt)(H2O)]0.5H2O 3315
- 
3667 
- 1593 - 952 - - 
Zn2[(Mp(Smdt)2)(CH3COO)] - - 1613 - 1000 1460 1375 
Zn[(VanSmdt)(H2O)] 3427 - 1597 - 1034 - - 
Zn[(PySmdt)(CH3COO)]1.5H2O 3417 - - 1597 1022 1493 1304 
 
The compounds were also characterized by NMR spectroscopy. The spectra of ligands and their 
corresponding zinc complexes were recorded at room temperature in acetone-d6 (SalSmdt, 
VanSmdt and their complexes) and in DMSO-d6 (Mp(Smdt)2, PySmdt and their complexes).  
The chemical shift of protons and carbons for both ligands and complexes are described in detail 
in the experimental part. In this section, only the 1H and 13C NMR spectral data of selected 
groups are presented in Table 10. The aromatic protons and carbons of the ligands were 
observed in the range 6.90-8.81 ppm and 114.86-156.72 ppm, respectively. In their zinc 
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complexes, the chemical shift of these protons and carbons were found between 6.39-7.43 ppm 
and 113.17-165.1 ppm, respectively.  Mp(Smdt)2  and PySmdt showed characteristic proton 
signals at 2.30 and 2.42 ppm, respectively, attributed  to  the methyl (CH3) moiety (a substituent 
on the aromatic  group). In their corresponding complexes, these protons were observed at 2.24 
ppm (Zn2[(Mp(Smdt)2)(CH3COO)]) and 2.39 ppm (Zn[(PySmdt)(CH3COO)]). The carbon 
signals of this group were found at 19.79 ppm (Mp(Smdt)2)  and 19.18 ppm (PySmdt). In the 
spectra of their complexes, the carbon signals of this methyl group appeared at 19.36 ppm 
(Zn2[(Mp(Smdt)2)(CH3COO)]) and 21.35 ppm (Zn[(PySmdt)(CH3COO)]). The proton signals 
observed at 3.87 ppm in VanSmdt and 3.72 ppm in Zn[(VanSmdt)(H2O)] are attributed to  the 
methoxy (OCH3) group.  The carbon signals of this methoxy group were displayed at 56.49 ppm 
and 55.65 ppm for VanSmdt and Zn[(VanSmdt)(H2O)], respectively. The proton and carbon 
signals of Ar-CH2 in PySmdt were observed at 4.63 ppm and 59.21 ppm, respectively. In its 
corresponding complex (Zn[(PySmdt)(CH3COO)]) the proton and carbon signals of this group 
were found at 4.51 ppm and 59.51 ppm respectively.  
The ligands showed proton and carbon signals between 2.57-2.65 ppm and 16.80-17.52 ppm, 
respectively, which are attributed to S-CH3. The proton and carbon signals of this group in the 
complexes shift upfield to 2.41-2.44 ppm and 14.13-14.46 ppm, respectively. This indicates that 
the sulfur atom of the thione group is coordinated to the metal ion. Other distinctive signals 
appeared between 8.04-8.56 ppm in the ligands, attributed to -CH=N group and shifted 
downfield to 8.55-8.92 ppm in their corresponding zinc complexes. The signals of the carbon of 
this group also shifted downfield from 138.73-149.36 ppm in the ligands to 155.82-161.29ppm, 
in the complexes. In addition, proton signals appearing in the ligands between 12.25-13.74 ppm 
which are attributed to NH (from the dithiocarbazate) group, disappeared in their corresponding 
complexes except in Zn[(PySmdt)(CH3COO)], where it appears at 11.97 ppm. Besides this, in 
this complex there are other evidences that coordination is through NH-C=S (the thione 
tautomer), instead of N=C-S- (the thiol tautomer, see p.e. the elemental analysis and FTIR). 
Proton signals appearing in the ligand’s spectra between 9.65-10.81 ppm are attributed to OH 
(Ar-OH) group, and disappear in their corresponding zinc complexes, indicating that the ligands 
are coordinated to the metal ion through the phenolate group. In general, the chemical shift 
values and type of coordination are in agreement with that of previously reported values for 
similar compounds [25,30,32,78]. 
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Table 10: Selected 1H and 13C NMR spectral data for ligands and complexes 
 
Compound  
 
1H NMR chemical shift, δ (ppm) 
13C NMR 
chemical shift, δ 
(ppm) 
SCH3 HC=N NH Ar-OH SCH3 HC=N 
SalSmdt 2.65 8.52 12.25 10.24 17.52 149.36 
Mp(Smdt)2 2.57 8.52 13.51 10.81 16.80 144.75 
VanSmdt 2.63 8.56 13.34 9.65 17.18 148.74 
PySmdt 2.61 8.04 13.74 10.61 17.12 138.73 
Zn[(SalSmdt)(H2O)] 2.44 8.73 - - 14.46 161.29 
Zn2[(Mp(Smdt)2)(CH3COO)] 2.43 8.69 - - 13.95 159.64 
Zn[(VanSmdt)(H2O)] 2.41 8.55 - - 14.17 159.84 
Zn[(PySmdt)(CH3COO)] 2.44 8.92 11.97 - 14.13 155.82 
 
3.2.2. Stability 
Evaluation of the stability of all S-methyl dithiocarbazate derived Schiff base ligands and their 
zinc(II) complexes under investigation was carried out using UV-Visible spectrophotometry in 
aqueous solution (5 % DMSO and 95 % PBS), except for Zn2[(Mp(Smdt)2)(CH3COO)] which 
was done only in DMSO (because of solubility problem) at room temperature.  The UV-Visible 
absorption spectra (260-500 nm) were recorded and monitored for 24 h for ligands and 48 h for 
complexes of which the detailed procedure is described in the experimental part. The shape of 
the spectra of the ligands and zinc complexes did not show any change as it is depicted in Figure 
24. The UV-Vis absorption intensity of these compounds also did not show significant changes 
in the first 3 h. Only small intensity changes were observed for longer periods, probably due to 
precipitation (not detected by visual inspection). Therefore, it can be concluded that the Schiff 
base ligands and their zinc(II) complexes are reasonably stable in aqueous physiological 
conditions.  
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Figure 24 UV-Vis absorption spectra of solutions containing 100 µM Smdt (a), 12.5 µM 
Mp(Smdt)2 (b), 12.5 µM SalSmdt (c), 100 µM  VanSmdt (d), 12.5 µM PySmdt (e) 25 µM  
Zn[(SalSmdt)(H2O)] (f), 25 µM Zn2[(Mp(Smdt)2)(CH3COO)] (g), 25 µM Zn[(VanSmdt)(H2O)] 
(h) and 100 µM Zn[(PySmdt)(CH3COO)] (i) with increasing time (t0, 30 min, 2 h, 3 h, 4 h and 
24 h for ligands; and t0, 5 min, 10 min, 20 min, 30 min, 1 h, 2 h; 3 h, 4 h , 24 h and 48 h for 
complexes) in  5% DMSO and 95 %  PBS but (g)  in DMSO only. 
The stability of the S-methyl dithiocarbazate derived Schiff base ligands and their corresponding 
zinc complexes was further evaluated using RP-HPLC at room temperature. The RP-HPLC 
analysis was carried out using the procedure described in the experimental section in detail. The 
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chromatograms of SalSmdt and VanSmdt
base ligands no peaks corresponding to hydrolysis products being observed (p.e.
and smdt, or o-vanillin and smdt, respectively)
Zn[(VanSmdt)(H2O)] also showed a single peak corresponding to the zinc complex
depicted in Figure 25. The retention times for the ligands and complexes are similar and 
therefore determined by the ligand interactions with the stationary and mobile phases.
chromatogram of Mp(Smdt)2 showed three peaks
compound Smdt, the expected ligand itself
Schiff base. In the chromatogram of 
starting compound Smdt and the ligand itself.  
Zn2[(Mp(Smdt)2)(CH3COO)] and 
corresponding to the complex and other dissociated species
single peak indicates that the compounds are stable but 
are not stable under these chromatographic conditions.
 
 
 showed only a single peak corresponding
. The Zn[(SalSmdt
, which may be attributed to the starting
 and other  hydrolyzed species, possibly the “mono” 
PySmdt, two peaks were observed corresponding
The chromatograms of 
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those, which showed two
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Figure 25 RP-HPLC chromatograms of reagents, S
ligands and their zinc complexes
min. 
3.2.3. Antioxidant activity
The antioxidant activity of the 
corresponding zinc complexes were also evaluated by 
procedure described in the experimental section. 
test compounds and DPPH in different molar
Then, by following the absorption intensity trend at 516 nm, 
radical scavenging ability of the test compounds using
were determined by a linear regression where the % of scavenging activity is 50 and compared 
with the IC50 value of ascorbic acid (
All the spectra measured with solutions
decrease in the absorption intensity at 516
complexes, except Zn[(PySmdt)(CH
values of the Schiff base ligands and their
acid are presented in Table 11.  
 
 
-methyl dithiocarbazate derived Schiff base 
, eluted with 50% CH3CN: 50% H2O at a flow rate of 1 ml / 
 
S-methyl dithiocarbazate derived Schiff base ligands and their 
the DPPH scavenging assay,
The absorption spectra of the 
 ratios were scanned between 300 and 700 nm. 
it was possible to evaluate the free 
 Equation 3. Moreover, the values for IC
the positive control).  
 containing the studied Schiff base ligands showed
 nm (Figure 26) but their corresponding zinc 
3COO)], do not show any significant decrease. 
 corresponding zinc complexes, along with 
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Figure 26 UV-Vis absorption spectra measured for solutions containing DPPH (6
MeOH) and different % (n(compound) / n(DPPH)) of compounds. 
scavenging activity vs. [compounds] for the DPPH assay, from which the IC
obtained 
 
 
Inset: Linear regression of % 
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Table 11:  IC50 values and molar ratio of compound to DPPH obtained from the DPPH assays 
for the synthesized S-methyl dithiocarbazate derived Schiff base ligands, their zinc(II) 
complexes and ascorbic acid 
Compound IC50 (µM) n(comp) / n(DPPH) 
SalSmdt 43.1 0.59 
Mp(Smdt)2 42.1 0.58 
VanSmdt 42.4 1.51 
PySmdt 38.4 1.37 
Zn[(SalSmdt)(H2O)] na na 
Zn2[(Mp(Smdt)2)(CH3COO)] na na 
Zn[(VanSmdt)(H2O)] na na 
Zn[(PySmdt))(CH3COO)] 400.7 5.33 
Ascorbic acid 16.1 0.21 
             ‘na’-no antioxidant activity  
From the results it can be concluded that, the presence of phenol substituents on the aromatic 
ring enabled the ligands to have free radical scavenging activity. This is the reason why a 
considerable increase in the percent of scavenging activity was found with increasing 
concentration of the S-methyl dithiocarbazate derived Schiff base ligands. But in the complexes, 
this phenol group is unavailable since it is coordinated to zinc ion. Because of this reason, the 
zinc complexes, except Zn[(PySmdt))(CH3COO)] did not show any free radical scavenging 
activity. All the IC50 values of the compounds, which showed scavenging activity, are greater 
than the IC50 value of the control (ascorbic acid). Hardly any differences are found among the 
ligands with different substituents in the aromatic moiety. 
3.2.4. Phosphatase activity studies    
The phosphatase activity of the zinc complexes of the S-methyl dithiocarbazate Schiff bases was 
also evaluated using the disodium salt of (4-nitrophenyl) phosphate hexahydrate (PNPP) as 
monophosphate ester substrate, following the procedure described in the experimental section. 
None of the compounds showed an increase in UV-visible absorption between 400-430 nm, 
which in turn indicates that they do not have any phosphatase activity.  As an example, the 
spectra measured for Zn2[Mp(smdt)2] are shown in  Figure 27.   
  
Figure 27 Wavelength scan for the hydrolysis of PNPP in the absence and presence of 
Zn2[(Mp(Smdt)2)(CH3COO)] in 
minutes. [PNPP] = 0.5 mM, [Complex] =0.05
3.3. Cytotoxicity
The cytotoxicity of the Schiff bases w
cells. The evaluation was also done for 
comparative purposes. The antiproliferative effects of the Schiff bases were determined by the 
MTT assay at incubation period of 48 h 
sigmoidal fitting considering 95 
shown are representative of at least two independent experiments.   
Table 12: Estimated IC50 values (µM) for all compounds in PC
Compound 
PC-3 
IC50 
SalSmdt 4.41 
Mp(Smdt)2 9.73 
VanSmdt 28.99 
PySmdt >100 
5-FU 3.30 
 
PBS recorded at 25 oC at an interval f 10 min
 mM. 
 studies 
as evaluated on human PC-3, MCF-7 and CACO
5-fluorouracil (5-FU, the positive control)
for all cell lines.  The IC50 values were calculated by 
% confidence interval and are presented in Table 
 
-3, MCF-7 and CACO
MCF-7 CACO-2
R2 IC50 R
2 IC50 
0.99 - - - 
0.98 14.94 1 12.58 
0.99 - - 22.12 0.99
- - - - 
1 4.93 0.99 0.82 0.99
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The cytotoxicity effect of Zn(II)(Rphen) complexes was also  evaluated on human A2780 
ovarian  cancer cell line using MTT assay at different  incubation periods and compared with that 
of their corresponding ligands.  The cytotoxicity of the compounds is presented in Table 13.  
Table 13: Estimated IC50 values (µM) for Zn(II)(Rphen) complexes compared to IC50 values of 
their corresponding ligands on A2780 cell line  
Compound 3h 24h 48h 
Zn(phen)2 >100 103±59.5 2.40±1.3 
Zn(Mephen)2 121±68.2 22.9±16.5 0.19±0.08 
Zn(aminophen)2 61.6±23.6 33.4±16.7 0.75±0.13 
phen >100 134±62 5.84±2.3 
Mephen 37.4±8.1 14.0±5.1 1.42±0.41 
aminophen >100 40.6±29.4 1.84±0.56 
 
As it can be seen from the above tables, all the Schiff bases,  with the exception of  PySmdt (IC50 
> 100 μM) have shown cytotoxicity effect on the tested cell lines with IC50 values ranging from 
4.41 to 28.99 μΜ after 48 h. The salicylaldehyde Schiff base, SalSmdt shows an IC50 value on 
the μΜ range against the PC-3 cell line, comparable with the one obtained for the positive 
control, 5-fluorouracil. The antiproliferative studies with the Zn-complexes are currently 
ongoing. 
Similarly, Zn(Rphen)2 complexes have shown cytotoxicity effect on the human ovarian 
carcinoma cell line, A2780, with the IC50 values ranging from 0.19 to 2.4 μΜ after 48 h. The 
phenanthroline ligands have also shown cytotoxicity effect on the same cell line with IC50 values 
ranging from 1.42 to 5.84 μΜ. However, taking into consideration that each metal complex 
contains two ligands coordinated to the metal ion, and that the ligands itself are cytotoxic, for a 
synergistic effect to take place the IC50 value of the complexes should be at least half of the 
respective ligand. This is what happens at longer time intervals (48h).  
In general, the cytotoxicity effect of both the Schiff bases and the zinc(II) complexes with 
phenanthroline ligands on tested cancer cells  is promising and can be  used as basis for further 
studies.  
 68 
 
4. Conclusion 
 In the current work four new S-methyl dithiocarbazate Schiff base derived ligands were 
synthesized: SalSmdt, Mp(Smdt)2, VanSmdt and PySmdt; and four corresponding Zn(II) 
complexes:  Zn[(SalSmdt)(H2O)]0.5H2O, Zn2[(Mp(Smdt)2)(CH3COO)], Zn[(VanSmdt)(H2O)] 
and Zn[(PySmdt)(CH3COO)]1.5H2O. Three zinc(II) complexes: Zn[(phen)2(NO3)2]2H2O, 
Zn[(aminophen)2(NO3)2]1.5H2O and Zn[(Mephen)2(NO3)2]3.5H2O were also developed by 
reaction of Zn(NO3)24H2O with commercially available phenanthroline derived ligands.   
All compounds were successfully characterized by the usual elemental and spectroscopic 
techniques. The characterization suggests that the Schiff base ligands coordinate the metal ion 
through the phenolate-O, the imine-N and sulfur atom in the thiol form (except in 
Zn[(PySmdt)(CH3COO)] for which a thione form is proposed).  The Zn(II) ion has coordination 
number four, with the ligands  tridentate and a water molecule or an acetate ion occupying the 4th 
coordination position. On the other hand, characterization showed that the phenanthroline 
derivative ligands coordinate the metal ion through the two nitrogen atoms of the aromatic ring. 
Characterization with 1H and 13C NMR proved that in solution there is formation species of 
different stoichiometries, which correspond to 1:1, 1:2 and 1: 3 Zn:L molar ratios.  
The stability of the compounds in buffered aqueous media (5 % DMSO and 95 % PBS) was 
evaluated and all are stable at least for three hours. The antioxidant potential of the compounds 
was tested using the DPPH assay. All S-methyl Schiff bases showed moderate antioxidant 
activity but the Zn(II) complexes, with the exception of Zn[(PySmdt)(CH3COO)], are inactive. 
The Zn(II) phenanthroline complexes were tested for their DNA binding ability. The results 
indicated that there is interaction between the complexes and ctDNA. The cytotoxicity effect 
against tumor cells was also evaluated. The Schiff bases have shown promising results with IC50 
values ranging from 4.41 to 28.99 μM on cell lines (PC-3, MCF-7 and CACO-2) after 48 h. The 
IC50 values of Zn(II) phenanthroline complexes on A2780 cell line ranged from 0.19 to 2.4 μΜ 
after 48 h, which indicate that the cytotoxicity effect is slightly greater than that of the  ligands, 
at least for longer times. Cytotoxicity study of zinc(II)-Schiff base complexes is still ongoing.  
In general, both families of compounds show potential to proceed further for biological studies to 
allow their development as metallodrugs, particularly the phenanthroline Zn(II) compounds. 
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Appendices 
In the following appendices several data is included, namely: 
A – NMR spectra 
B – ESI-MS spectra 
C – FTIR spectra 
D – RP-HPLC chromatograms. 
 
A. NMR spectra  
 
Figure A 1 1H NMR spectrum of phen in DMSO-d6 at room temperature  
 
Figure A 2 13C NMR spectrum of phen in DMSO-d6 at room temperature 
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  Figure A 3 1H NMR spectrum of Zn[(phen)2(NO3)2]2H2O in DMSO-d6 at room temperature 
  
 
                        Figure A 4  13C NMR spectrum of Zn[(phen)2(NO3)2]2H2O in DMSO-d6 at 
room temperature  
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Figure A 5 COSY NMR spectrum of Zn[(phen)2(NO3)2]2H2O in DMSO-d6 at room 
temperature 
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Figure A 6 HSQC NMR spectrum of Zn[(phen)2(NO3)2]2H2O in DMSO-d6 at room 
temperature 
 
Figure A 7 HMBC NMR spectrum of Zn[(phen)2(NO3)2]2H2O in DMSO-d6 at room 
temperature 
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Figure A 8 COSY NMR spectrum of Zn[(aminophen)2(NO3)2]1.5H2O in CD3OD at room 
temperature 
 
Figure A 9 HSQC NMR spectrum of Zn[(aminophen)2(NO3)2]1.5H2O in CD3OD at room 
temperature 
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Figure A 10  COSY NMR spectrum of Zn[(Mephen)2(NO3)2]3.5H2O in CD3OD at room 
temperature  
 
Figure A 11  HSQC NMR spectrum of Zn[(Mephen)2(NO3)2]3.5H2O in CD3OD at 
room temperature 
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Figure A 12 HMBC NMR spectrum of Zn[(Mephen)2(NO3)2]3.5H2O in CD3OD at room 
temperature 
 
Figure A 13  1H NMR spectrum of Mp(Smdt)2 in DMSO-d6  at room temperature 
 
Figure A 14  13C NMR spectrum of Mp(Smdt)2 in DMSO-d6  at room temperature 
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Figure A 15 1H NMR spectrum of VanSmdt in acetone-d6 at room temperature 
 
Figure A 16 1H NMR spectrum of VanSmdt in DMSO-d6 at room temperature 
 
Figure A 17 13C NMR spectrum of VanSmdt in acetone-d6 at room temperature 
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Figure A 18 1H NMR spectrum of SalSmdt in acetone-d6 at room temperature 
 
Figure A 19 13C NMR spectrum of SalSmdt in acetone-d6 at room temperature 
 
Figure A 20 COSY NMR spectrum of SalSmdt in acetone-d6 at room temperature 
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Figure A 21 1H NMR spectrum of PySmdt in DMSO-d6  at room temperature 
 
Figure A 22 13C NMR spectrum of PySmdt in DMSO-d6 at room temperature 
 
    Figure A 23 1H NMR spectrum of Zn[(VanSmdt) (H2O)]  in DMSO-d6  at room temperature 
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   Figure A 24 13 C  NMR spectrum of Zn[(VanSmdt) (H2O)]  in DMSO-d6  at room temperature 
 
 
Figure A 25 1H NMR spectrum of Zn[(SalSmdt)(H2O)]0.5H2O in acetone-d6 at room 
temperature 
 
Figure A 26 13C NMR spectrum of Zn[(SalSmdt)(H2O)]0.5H2O in acetone-d6  at room 
temperature 
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Figure A 27 HSQC NMR spectrum of Zn[(SalSmdt)(H2O)]0.5H2O in acetone-d6  at room 
temperature 
 
Figure A 28 1H NMR spectrum of Zn[(PySmdt)(CH3COO)]1.5H2O in DMSO-d6  at room 
temperature 
 
Figure A 29 13C NMR spectrum of Zn[(PySmdt)(CH3COO)]1.5H2O in DMSO-d6  at room 
temperature 
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Figure A 30 HSQC NMR spectrum of Zn[(PySmdt)(CH3COO)]1.5H2O in DMSO-d6  at room 
temperature 
  
Figure A 31 HMBC NMR spectrum of Zn[(PySmdt)(CH3COO)]1.5H2O in DMSO-d6  at room 
temperature 
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Figure A 32  1H NMR spectrum of Zn2[(Mp(Smdt)2)(CH3COO)] in DMSO-d6  at room 
temperature 
    
Figure A 33 DEPT NMR spectrum of Zn2[(Mp(Smdt)2)(CH3COO)] in DMSO-d6 at room 
temperature 
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Figure A 34    HSQC NMR spectrum of Zn2[(Mp(Smdt)2)(CH3COO)] in DMSO-d6  at room 
temperature 
B. ESI-MS spectra  
 
Figure B 1 ESI(+)-MS spectrum  of Zn[(phen)2(NO3)2]2H2O 
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Figure B 2 ESI(+)-MS spectrum of Zn[(aminophen)2(NO3)2]1.5H2O 
 
 
Figure B 3  ESI(+)-MS spectrum of Zn[(Mephen)2(NO3)2]3.5H2O 
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Figure B 4 ESI(-)-MS spectrum of VanSmdt 
   
Figure B 5  ESI(+)-MS spectrum of VanSmdt 
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Figure B 6  ESI(+)-MS spectrum of Zn[(PySmdt)(CH3COO)]1.5H2O 
  
Figure B 7 ESI(-)-MS spectrum of PySmdt 
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Figure B 8  ESI(+)-MS spectrum of PySmdt 
 
Figure B 9  ESI(-)-MS spectrum of  SalSmdt 
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Figure B 10  ESI(+)-MS spectrum of  SalSmdt 
 
Figure B 11 ESI(-)-MS spectrum of  Zn[(VanSmdt)(H2O)] 
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Figure B 12 ESI(-)-MS spectrum of  Mp(Smdt)2 
  
Figure B 13 ESI(+)-MS spectrum of  Mp(Smdt)2 
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Figure B 14  ESI(-)-MS spectrum of  Zn2[(Mp(Smdt)2)(CH3COO)] 
 
Figure B 15 ESI(+)-MS spectrum of  Zn2[(Mp(Smdt)2)(CH3COO)] 
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Figure B 16  ESI(-)-MS spectrum of  Zn[(SalSmdt)(H2O)]0.5H2O 
 
Figure B 17 ESI(+)-MS spectrum of  Zn[(SalSmdt)(H2O)]0.5H2O 
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C. FTIR Spectra   
 
Figure C 1  FTIR spectra of phen and Zn[(phen)2(NO3)2]2H2O 
 
Figure C 2 FTIR spectra of aminophen and Zn[(aminophen)2(NO3)2]1.5H2O 
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Figure C 3 FTIR spectra of Mephen and Zn[(Mephen)2(NO3)2]3.5H2O 
 
 
 
 
 
Figure C 4 FTIR spectra of Mp(Smdt)2  and Zn[(Mp(Smdt)2(CH3COO)] 
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Figure C 5 FTIR spectra of SalSmdt  and Zn[(SalSmdt)(H2O)]0.5H2O 
 
 
Figure C 6 FTIR spectra of VanSmdt and Zn[(VanSmdt)(H2O)] 
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Figure C 7 FTIR spectra of PySmdt and Zn[(PySmdt)(CH3COO)]1.5H2O 
D. RP-HPLC chromatogram  
 
Figure D 1 RP-HPLC chromatograms of 2,6-diformyl-4-methylphenol, Smdt , Mp(Smdt)2 and 
Zn2[(Mp(Smdt)2)(CH3COO)], eluted with 50% CH3CN: 50% H2O at a flow rate of 1 ml / min. 
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Figure D 2 RP-HPLC chromatograms of Pyridoxal hydrochloride, Smdt , PySmdt and 
Zn[(PySmdt)(CH3COO)]1.5H2O, eluted with 50% CH3CN: 50% H2O at a flow rate of 1 ml / 
min. 
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